CA2464485C - Microneedle transdermal transport device - Google Patents
Microneedle transdermal transport device Download PDFInfo
- Publication number
- CA2464485C CA2464485C CA2464485A CA2464485A CA2464485C CA 2464485 C CA2464485 C CA 2464485C CA 2464485 A CA2464485 A CA 2464485A CA 2464485 A CA2464485 A CA 2464485A CA 2464485 C CA2464485 C CA 2464485C
- Authority
- CA
- Canada
- Prior art keywords
- transport device
- needle
- transdermal transport
- formulation
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/155—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by gas introduced into the reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M2005/1401—Functional features
- A61M2005/1405—Patient controlled analgesia [PCA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14204—Pressure infusion, e.g. using pumps with gas-producing electrochemical cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
- A61M2005/14252—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14268—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with a reusable and a disposable component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
- A61M2005/1581—Right-angle needle-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0038—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0266—Shape memory materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/65—Impedance, e.g. conductivity, capacity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
Abstract
A transdermal transport device includes a reservoir for holding a formulation of an active principle, and a needle (14) with a bore extending along the length of the needle from a first end of the needle to a second end of the needle. The second end is substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface.
The device also includes an actuator which pumps the formulation through the bore of the needle between a target area of the body and the reservoir.
The device also includes an actuator which pumps the formulation through the bore of the needle between a target area of the body and the reservoir.
Description
MICRONEEDLE TRANSDERMAL TRANSPORT DEVICE
BACKGROUND
S Delivery of drugs to a patient is performed in a number of ways. For example, intravenous delivery is by injection directly into a blood vessel;
intraperitoneal delivery is by injection into the peritoneum; subcutaneous delivery is under the skin; intramuscular is into a muscle; and orally is through the mouth. One of the easiest methods for drug delivery, and for collection of body fluids, is through the skin.
Skin is the outermost protective layer of the body. It is composed of the epidermis, including the stratum corneum, the stratum granulosum, the stratum spinosum, and the stratum basale, and the dermis, containing, among other things, the capillary layer. The stratum corneum is a tough, scaly layer made of dead cell 1 S tissue. It extends around 10-20 microns from the skin surface and has no blood supply. Because of the density of this layer of cells, moving compounds across the skin, either into or out of the body, can be very difficult.
The current technology for delivering local pharmaceuticals through the skin includes both methods that use needles or other skin piercing devices and methods that do not use such devices. Those methods that do not use needles typically involve: (a) topical applications, (b) iontophoresis, (c) electroporation, (d) laser perforation or alteration, (e) carriers or vehicles, which are compounds that modify the chemical properties of either the stratum corneum and/or the pharmaceutical, S (f) physical pretreatment of the skin, such as abrasion of the stratum corneum (e.g.
repeatedly applying and removing adhesive tape), and (g) sonophoresis, which involves modifying the barrier function of stratum corneum by ultrasound.
Topical applications, such as a patch, or direct application of a pharmaceutical to the skin, depend on diffusion or absorption through the skin.
These methods of transdermal transport are not widely useful because of the limited permeability of the stratum corneum. Although techniques such as those listed above have been developed to enhance the effectiveness of topical applications, topical applications still cannot provide optimum transdermal transport.
On the other hand, invasive procedures, such as use of needles or lances, effectively overcome the barrier function of the stratum corneum. However, these methods suffer from several major disadvantages: pain, local skin damage, bleeding, and risk of infection at the injection site, and creation of contaminated needles or lances that must be disposed of. These methods also usually require a trained administrator and are not suitable for repeated, long-term, or controlled use.
Additionally, drug delivery through the skin has been relatively imprecise in both location and dosage of the pharmaceutical. Some of the problems include movement of the patient during administration, delivery of incomplete dosages, difficulties in administering more than one pharmaceutical at the same time, and difficulties in delivering a pharmaceutical to the appropriate part of the skin. Drugs have traditionally been diluted to enable handling of the proper dosages. This dilution step can cause storage as well as delivery problems. Thus, it would be advantageous to be able to use small, precise volumes of pharmaceuticals for quick, as well as long-term, delivery through the skin.
BACKGROUND
S Delivery of drugs to a patient is performed in a number of ways. For example, intravenous delivery is by injection directly into a blood vessel;
intraperitoneal delivery is by injection into the peritoneum; subcutaneous delivery is under the skin; intramuscular is into a muscle; and orally is through the mouth. One of the easiest methods for drug delivery, and for collection of body fluids, is through the skin.
Skin is the outermost protective layer of the body. It is composed of the epidermis, including the stratum corneum, the stratum granulosum, the stratum spinosum, and the stratum basale, and the dermis, containing, among other things, the capillary layer. The stratum corneum is a tough, scaly layer made of dead cell 1 S tissue. It extends around 10-20 microns from the skin surface and has no blood supply. Because of the density of this layer of cells, moving compounds across the skin, either into or out of the body, can be very difficult.
The current technology for delivering local pharmaceuticals through the skin includes both methods that use needles or other skin piercing devices and methods that do not use such devices. Those methods that do not use needles typically involve: (a) topical applications, (b) iontophoresis, (c) electroporation, (d) laser perforation or alteration, (e) carriers or vehicles, which are compounds that modify the chemical properties of either the stratum corneum and/or the pharmaceutical, S (f) physical pretreatment of the skin, such as abrasion of the stratum corneum (e.g.
repeatedly applying and removing adhesive tape), and (g) sonophoresis, which involves modifying the barrier function of stratum corneum by ultrasound.
Topical applications, such as a patch, or direct application of a pharmaceutical to the skin, depend on diffusion or absorption through the skin.
These methods of transdermal transport are not widely useful because of the limited permeability of the stratum corneum. Although techniques such as those listed above have been developed to enhance the effectiveness of topical applications, topical applications still cannot provide optimum transdermal transport.
On the other hand, invasive procedures, such as use of needles or lances, effectively overcome the barrier function of the stratum corneum. However, these methods suffer from several major disadvantages: pain, local skin damage, bleeding, and risk of infection at the injection site, and creation of contaminated needles or lances that must be disposed of. These methods also usually require a trained administrator and are not suitable for repeated, long-term, or controlled use.
Additionally, drug delivery through the skin has been relatively imprecise in both location and dosage of the pharmaceutical. Some of the problems include movement of the patient during administration, delivery of incomplete dosages, difficulties in administering more than one pharmaceutical at the same time, and difficulties in delivering a pharmaceutical to the appropriate part of the skin. Drugs have traditionally been diluted to enable handling of the proper dosages. This dilution step can cause storage as well as delivery problems. Thus, it would be advantageous to be able to use small, precise volumes of pharmaceuticals for quick, as well as long-term, delivery through the skin.
SUMMARY
The present invention implements an effective, multi-application microneendle transport system, which provides painless, precision insertion and controlled, programmable transport at commercially viable costs.
The microneedle transport device includes, at its most basic level, one or more microneedles connected to at least one reservoir. The microneedles can be provided in one or more rows or arrays. The arrays can be arranged in a Cartesian or circular pattern. A system for delivering substances to or withdrawing fluids from a patient can further include one or more actuators, pumps, and/or sensors.
These elements can be combined in a variety of ways to produce systems with different attributes for delivery and/or collection of substances or information through the skin.
The microneedle transport device disclosed herein may have several applications, including but not limited to drug delivery, sampling, and biological 1 S monitoring. In application as a drug delivery device, each reservoir is filled with one or more drugs to be delivered. In sampling, each reservoir is initially empty and then filled with biological material, such as interstitial fluid. In monitoring, the device is adapted with sensors to monitor, for example, the concentration of a compound, such as glucose, in fluid that has been withdrawn, or with some receptor on the needle going into the skin (i.e., the fluid doesn't have to be withdrawn necessarily).
In one embodiment, the device includes a reservoir for holding a formulation of an active principle, and a needle with a bore extending along the length of the needle from a first end of the needle to a second end of the needle that is substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface. The device also includes an actuator which pumps the formulation through the bore of the needle between a target area of the body and the reservoir. The device can include one or more additional needles like the needle described above, thereby forming an array of needles. In particular embodiments, the actuator moves the first end into the reservoir so that the bore is in fluid communication with the reservoir.
The present invention implements an effective, multi-application microneendle transport system, which provides painless, precision insertion and controlled, programmable transport at commercially viable costs.
The microneedle transport device includes, at its most basic level, one or more microneedles connected to at least one reservoir. The microneedles can be provided in one or more rows or arrays. The arrays can be arranged in a Cartesian or circular pattern. A system for delivering substances to or withdrawing fluids from a patient can further include one or more actuators, pumps, and/or sensors.
These elements can be combined in a variety of ways to produce systems with different attributes for delivery and/or collection of substances or information through the skin.
The microneedle transport device disclosed herein may have several applications, including but not limited to drug delivery, sampling, and biological 1 S monitoring. In application as a drug delivery device, each reservoir is filled with one or more drugs to be delivered. In sampling, each reservoir is initially empty and then filled with biological material, such as interstitial fluid. In monitoring, the device is adapted with sensors to monitor, for example, the concentration of a compound, such as glucose, in fluid that has been withdrawn, or with some receptor on the needle going into the skin (i.e., the fluid doesn't have to be withdrawn necessarily).
In one embodiment, the device includes a reservoir for holding a formulation of an active principle, and a needle with a bore extending along the length of the needle from a first end of the needle to a second end of the needle that is substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface. The device also includes an actuator which pumps the formulation through the bore of the needle between a target area of the body and the reservoir. The device can include one or more additional needles like the needle described above, thereby forming an array of needles. In particular embodiments, the actuator moves the first end into the reservoir so that the bore is in fluid communication with the reservoir.
In certain embodiments, the second end of the needle moves in the plane to pierce the body surface. The actuator can pump the formulation into the biological body, and/or it can be reversible to draw the formulation into the vial. The needle can be positioned in a retracted state when the actuator is de-energized. A
rotary actuator can be used to move the second end of the needle in the plane.
The actuator can include a vapor generator, or alternatively, the actuator operates by an electrochemical process, or is a conductive polymer.
In some embodiments, the device includes an oscillator which causes the second end of the needle to vibrate along its length to reduce the force required to drive the needle into the body. The oscillator can be a piezoelectric crystal which generates the vibration of the needles.
In certain embodiments, the device includes a sensor to monitor the status of a patient, for example, the glucose concentration of the patient. In such implementations, the formulation can be insulin pumped into the patient, with the amount of insulin pumped being based on the glucose concentration.
In another embodiment, the second end of the needle has tip end that is slanted and defines an opening from which the formulation is dispensed to control the direction of diffusion of the formulation into the body. The tip can be slanted between about 10° to 60°.
The second end of the needle can have a plurality of openings along its length such that the formulation is dispensed from and drawn through the plurality of openings.
There can be one to 20 openings that are spaced apart between about 100 ~,m to In yet other embodiments, the device includes a controller which directs the actuator to pump a desired amount of the formulation. The desired amount is dependent on input specifics of the body. The desired amount can be dispensed over a particular time period, lasting, for example, from 1 sec to 10 days. The desired amount of formulation can be dispensed incrementally over time. The body can be a human patient, such that the desired amount of the formulation is a sample collected from the patient drawn into the reservoir over a particular time period. The device can include a base unit that contains the needle, and a control unit that contains the controller. The base unit and the control unit can be separate connectable units.
Other embodiments are directed to methods of using the transdermal transport device described above.
Some embodiments of the invention may have one or more of the following advantages. The microneedle transport device disclosed here further presents the advantages of low manufacturing costs, and high efficiency. Particularly in regards to ease of use, the automated/mechanical system of the microneedle device reduces the error and uncertainty usually introduced by manual application. Very little (if any) pain, local damage, bleeding, or risk of infection is caused by the microneedles.
Additionally, no special training or expertise is required to use the microneedle transport device. The device may further be adapted for disposable single-use, partial or full reuse, short or long-term use, or continuous or intermittent transport, or some combination thereof. The device is able to deliver a range of drug types and viscosities with variable delivery. For example, a significant amount of drug can be delivered in the beginning followed by maintenance dosing. The delivery can be periodic, for example, every hour, or can be on demand. The device provides for controllable and precise drug delivery to a location below the outer surface of the skin of the patient. That is, any desirable delivery profile can be set, for example, constant or intermittent, for delivery to a desired location. The device can provide on-demand delivery, for example, by pushing a button, when a patient desires some sort of pain control.
Since a precise amount of volume of drug can be delivered, there is a low volume of wasted drug. In addition to delivering a precise volume of drug with a variety of delivery profiles, the device is able to deliver a range of drugs.
For example, the formulation may be a liquid, or a non-liquid that is reconstituted at delivery, or some combination thereof.
The device provides reduced pain as compared to traditional hypodermic injections, with minimal air injected under the skin. A user of the device is able to verify drug, dosing, expiration, etc. with, for example, a computer server via the Internet. The impedance testing provides a convenient way of determining the depth of penetration of the needles. The device is small and portable, and the geometry of the device makes it comfortable to wear. The device is inexpensive and easy to use, and, hence, increases patient compliance. In addition, since the microneedles are protected within the base portion, exposure to contamination and/or accidental contact with a patient or medical clinician is eliminated or minimized.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
FIG. 1 is a side schematic view of an applicator with a transdermal transport device in accordance with the invention.
FIG. 2A is a cross-sectional view of the transdermal transport device shown in FIG. 1.
FIG. 2B is a top view of the transdermal transport device shown in FIG. 1.
FIG. 2C is a bottom view of the transdermal transport device shown in FIG.
1.
FIG. 2D is a close-up view of a suction port shown in FIG. 2C illustrating a microneedle in retracted and protracted states.
FIG. 3 is a close-up view of a tip of a microneedle of the transdermal transport device shown in FIG. 1 shown penetrating the skin of a patient and dispensing a drug into the patient.
FIG. 4 is a close-up view of the tip of a microneedle of the transdermal transport device shown in FIG. 1.
FIG. 5 is a side view of an alternative embodiment of a microneedle in accordance with the invention.
FIG. 6A is a graph of the insertion force of a microneedle versus the penetration depth of the microneedle.
FIG. 6B-6I is a sequence of graphs of the insertion force of a microneedle versus the penetration depth of the microneedle for different diameter needles.
FIG. 7A is a view of an actuator of the transdermal transport device shown in FIG. 2A.
FIG. 7B is a graph of the voltage requirements of the actuator shown in FIG.
7A with stainless steel electrodes.
FIG. 7C is a graph of the voltage requirements of the actuator shown in FIG.
7A with Nichrome electrodes.
FIG. 8A is schematic of a circuit formed with electrodes of an impedance sensor of the transdermal transport device shown in FIG. 1 and the skin of a patient.
FIG. 8B is a schematic diagram of a circuit used for the impedance sensor in accordance with the invention.
FIG. 9A is a graph of the magnitude of the impedance measured by the impedance sensor of FIG. 8A versus frequency.
FIG. 9B is a graph of the impedance versus the penetration depth.
FIG. 10 is a cross-sectional view of an alternative embodiment of the transdermal transport device.
FIG. 11 is a cross-sectional view of yet another alternative embodiment of the transdermal transport device.
DETAILED DESCRIPTION OF THE INVENTION
A description of preferred embodiments of the invention follows.
Referring to FIG. 1, there is shown a transdermal transport device 10 mounted to a coupling 11 of an applicator 12 which is used to attach the transport device 10 to the skin of a biological body, such as a human patient.
Furthermore, the applicator 12 activates the device 10 to initiate the transport process before being disengaged from the device.
The device 10 includes an array of microneedles 14 for piercing the outer layers of skin of the patient and for delivering a formulation of an active principle such as pharmaceuticals through the skin to provide accurate delivery of the _g_ pharmaceuticals to the patient. Moreover, because of the shape and size of the needles and the minimal depth of penetration of the needles, contact between the needles and the nerve endings beneath the outer layer of the skin is minimized so that pain is reduced or absent in the patient. The pharmaceutical may be a liquid formulation, or it may be one or more non-liquid drugs that are reconstituted just before delivery.
The applicator 12 is powered by a set of batteries 16 and controlled by an embedded processor 18 positioned within a housing 20 which holds various other internal components of the applicator. A display 22, such as an LCD, mounted on top of the housing 20 communicates to a user the operating parameters of the transport device 10 and the applicator 12. The applicator 12 is able to communicate with a mother unit such as a PC and/or through the Internet with a communication card 24. In some embodiments, the communication card is an ethernet card.
Additionally or alternatively, the communication card can be a Bluetooth card which provides wireless communication capabilities.
The transport device 10 is mounted to the applicator 12 with an electromagnet 26. To disengage the transport device 10 from the applicator, voltage to the electromagnet is simply turned off to break the magnetic coupling between the top of the transport device 10 and the electromagnet 26. The applicator 12 also includes a vacuum pump 28 which draws a vacuum through a suction port 41 (FIG.
2A) to create a suction between suction ports 60 (FIG. 2A) of the transport device 10 and the skin of the patient to attach the device 10 to the skin. The microneedles 14 are bent at about a 90° angle about 1/3 of the distance from the tip 62 to the other end 64 (FIG. 2A) of each microneedle. Accordingly, as a rotary actuator 30, such as a stepper motor, shape memory alloy, contractile polymer, rotary solenoid, or any other suitable rotary actuator, rotates the transport device 10 and thus moves the mirconeedles 14, they penetrate laterally into the skin since the suction produced by the vacuum pump 28 also draws the skin into the suction ports 60 above a plane defined by the tip portions 62 of the microneedles. An impedance sensor 32 is used to indicate when the microneedles have sufficiently penetrated into the skin.
A
piezoelectric or a speaker 34 is also used to provide audible, perhaps verbal, indications to the user. The operation of the transport device 10 and applicator 12 will be described below in greater detail.
Referring now to FIGS. 2A and 2B, in addition to a base portion 36 which holds the microneedles 14, the transport device 10 includes a control unit 38 and a drug vial 40. The control unit 38 is provided with electrical connections 42 which facilitate communication between the device 10 and the applicator 12, control electronics 43, and various sensors 44 that measure, for example, impedance, pressure, temperature, injection flow rate, as well as other sensors. Any of these sensors can also be located in the applicator 12, such as a pressure sensor 37. The control unit 38 also includes a power source 45 such as a supercapacitor and batteries which provide power to the device 10.
The drug vial 40 includes a drug chamber or reservoir 46 defined by a flexible membrane 48 and a rigid top section 50. Located above the drug vial 40 in the control unit 38 is an actuator 52. The actuator 52 is provided with a rigid base 54 that is joined to a cap 56 with a flexible bellow 58, or any other suitable expanding material, defining a chamber 59. As illustrated in FIGS. 2C and 2D, the suction ports 60 are located at the bottom of the base portion 36 to provide access for the tips 62 of the microneedles 14 to the skin.
In use, the applicator 12 is turned on by the user, such as a medical clinician, to activate the electromagnet 26 to attach the device 10 to the applicator 12.
The user then delivers the device 10 to the skin. Next, the vacuum pump 28 creates a vacuum seal through the vacuum ports 60 with the skin to hold the device 10 in place, and also to make the skin more accessible to the microneedles 14 as discussed above.
Referring to FIG. 3, the vacuum pump 28 draws a suction, indicated by the arrows A, in the ports 60 to bring the skin up to the necessary height in the ports.
The rotary actuator 30 then rotates and hence moves the microneedles 14 towards the skin in a direction at or about right angles to the direction of movement of the skin as it is sucked into the openings 60. Once the microneedles 14 contact the skin, they continue to move in the same direction approximately SO ~m to several mm into the skin, thereby penetrating the sidewall of the raised skin as illustrated in FIG. 4.
In one embodiment, the penetration depth is approximately 200 Vim. The extent of movement in this direction is dictated by the depth of the stratum corneum at the site where the microneedles 14 penetrate the skin. As stratum corneum depth varies, the applicator 12 uses the impedance sensor 32 to determine when the stratum corneum has been transversed. The impedance sensor 32 measures impedance of electric current flow between two of the microneedles 14. Impedance is high in the stratum corneum, and drops dramatically in the portion of the dermis just below the stratum corneum (see, e.g., FIG. 9B which shows a drop of approximately three orders of magnitude). The sensor 32 reads the change in impedance as the microneedles 14 penetrate into the skin, and movement is stopped when the impedance drops by an order of magnitude. Additionally or alternatively, there can be a hard mechanical stop, for example, the top of the ports 60, that prevents the microneedles from penetrating too deeply.
At this point, the vacuum pump 28 and the electromagnet 26 are de-activated to disengage the device 10 from the applicator 12. The vacuum seal between the device 10 and the skin is no longer needed to secure the device to the skin since the device 10 is now attached to the skin with the microneedles 14 The control unit 38 of the device 10 then activates the actuator 52 which operates in the illustrated embodiment by an electrolytic process to cause the volume within the chamber 59 to increase and hence forcing the cap 56 against the rigid top section 50 of the drug vial 40, thereby pushing the drug vial 40 downwards.
Consequently, the flexible membrane 48 is pushed against a bowed section 68 of a base plate 39, while the ends 64 of the microneedles 14 pierce through the membrane 48 and into the reservoir 46. Compression of the membrane 48 into the reservoir 46 expels the pharmaceutical through hollow pathways or bores of the microneedles into the skin. Thus, the device is able to deliver a pharmaceutical to a precise location just below the stratum corneum of the skin, as indicated by the letter B in FIG. 3.
Once the correct dose of the pharmaceutical is delivered, the device 10 is re-attached to the applicator 12 and the rotary actuator 30 moves the microneedles out of the skin to disengage the device 10 from the patient. Typically, the base portion 36 and the drug vial 40 are discarded, while the control unit 38 is re-used.
The device 10 is used to deliver precise amounts of drugs as needed by a patient.
Information relating to the patient can be relayed through an associated computer to the device 10 and the applicator 12 via the communication card 24.
The same device 10 can be used for collecting fluid, such as interstitial fluid, from the dermis. For collection to occur, the reservoir 46 must first be compressed.
This is accomplished by moving the drug vial 40 downward with the actuator SO
such that the membrane 48 of the reservoir 46 is compressed to expel any air in the reservoir 46. Upon penetration of the microneedles into the skin, the expansion chamber 59 of the actuator 52 is contracted to allow the drug vial 40 to rise which creates a vacuum inside the reservoir 46 to draw fluid through the microneedles into the reservoir 46.
Thus, the actuator 52 acts as a pump which facilitates pumping a drug through the microneedles into the skin or collecting a sample from the patient. The actuator 52 can be used to create a vacuum within the reservoir 46 before the device 10 is placed against the skin. In sum, the actuator 52 provides controlled, programmable transport to and from the target site.
The various features of the transport device 10 and the applicator 12 will now be described in greater detail.
In the present application, the term "microneedle" is intended to be construed as singular or plural, unless specifically modified by a term indicating the number of microneedles. Microneedles disclosed herein may be porous or non-porous, uniform or of varying diameters or cross-sectional geometries, or some combination thereof.
Hollow microneedles with uniform diameter are sometimes referred to as microtubes. As used herein, the term "microneedle" refers to both microtubes and any other kind of microneedle as described previously. Additionally, microneedles may also have openings at either or both ends, as well as, on the side-walls at various and/or multiple positions along the length, or any combination thereof.
Further, either or both ends of the microneedle may be flat, tapered to a point, rounded, or beveled from one or more sides, as described below.
As shown in FIG. 4, the tip 62 has an opening 71 and is cut at an angle, a, of approximately 10° to 60°, to provide a slanted surface 66a. This surface 66a and/or the outer surface 66b can be beveled. The illustrated embodiment has four microneedles 14, but there can be ten microneedles or more. The microneedles are metal welded or soldered to the base plate 39, made from, for example, stainless steel, of the base portion 36, and the bellows 58 is formed of a polymer and is ultrasonic welded to the base 54 and the cap 56 of the actuator 52, or the bellow can be permanently attached to either the control unit 38 or the drug vial 40.
Alternatively, these parts may be fitted together via a thermal seal or any other suitable technique for forming a fluid-tight seal. Note that the device 10 is in use or not, the microneedles 14 are always contained within the base portion 36 and never extend outside of the suction ports 60 beyond the bottom of the base portion 36.
This minimizes or eliminates contamination of the microneedles and accidental contact between the needles and a patient or medical clinician.
1 S The beveled surfaces 66a and/or 66b of the tip 62 has many advantages. It reduces the trauma to the skin; it further reduces any pain felt by the subject; it prevents coring of the tissue into the microneedle; and it decreases the amount of force required for penetration into the skin. Particularly, in regards to coring, sharp tipped microneedles having a small inner diameter are less likely to accumulate tissue within the hollow opening, thereby avoiding transport blockage. In the above embodiment, both ends of each microneedle 14 are sharpened: one end for insertion into the skin, and the other end for insertion through membrane 48 into the reservoir 46.
In certain embodiments, as illustrated in FIG. 5, the microneedles 14 can have holes 73 on the side-walls at various andlor multiple positions along the length through which fluid can be transmitted, combined with the openings 71 (FIG. 4) or with solid tips 75. There can be from one to 20 or more holes 73. The spacing between the holes is approximately in the range of 100 p.m to 2 mm.
The microneedles 14 may be manufactured from a variety of materials and by a variety of methods. Representative materials include metals, ceramics, semiconductors, organics, biodegradable and non-biodegradable polymers, glass, quartz, and various composites. Representative methods include micro-fabrication techniques. In the above illustrated embodiment, the microneedles 14 are made of medical grade stainless steel, such as 304 stainless steel. Stainless steel microneedles are advantageous because they are durable, semi-flexible, and have the mechanical strength to endure insertion into the stratum corneum. They can be cut from readily available, relatively inexpensive commercial stock via a chemical saw, or any suitable technique, to the desired dimensions, and ground to the desired tip geometry.
The microneedles 14 have an inner diameter of about 10 p,m to 100 p,m, an outer diameter of 30 pm to 250 pm, and a length of approximately 5 mm to 10 mm.
In the above illustrated embodiment, each of the microneedles has an inner diameter of 54 Vim, and an outer diameter of 108 Vim. Other embodiments use microneedles with an inner diameter of about 100 pm and outer diameter of about 175 pm.
The microneedles 14 can also be coated on the outside, the inside, or both.
Coatings can cover part or all of either or both surfaces. Coatings can be selected from, but are not limited to, the group consisting of lubricants, chemical or biological reaction elements, and preservatives.
The microneedles may be made of one or more rows of microneedles of uniform or varying dimensions and geometries, with uniform or varying spacing, at uniform or varying projection angles, and any combination thereof. In the embodiment above, the set of microneedles form a circular array of four microneedles. The array has a radius of approximately 5 mm to 20 mm. In the illustrated embodiment, the radius is about 12 mm. In another embodiment, the set may include more than one circular array of microneedles. In yet another embodiment, the microneedles are arranged in an X by Y array, where X may or may not equal Y.
Additionally, as described above, the microneedle is bent, at approximately a 90° angle. As shown in FIG. 3, the bend of around 90° is positioned such that the segment from the bend to the tip 62 of the microneedle is long enough to penetrate through the stratum corneum. However, the angle, curvature, and location of the bend in the microneedle, as well as the orientation of the microneedle with respect to the device 10, can vary. For example, the bend angle may be 90° or more or less, but typically less than 180°.
In the bent microneedle embodiment, the bevel side 66a faces away from the bend and towards the skin surface, prior to insertion of the microneedle into the skin, and continues to face away from the rest of the device once it is inserted.
Penetration occurs at "acute-angle insertion" of the microneedle. The angle of insertion, p, (FIG. 3) is the angle formed by the skin surface and the microneedle 14, with the vertex of the angle at the point of contact between the microneedle and the skin surface. Acute-angle insertion reduces the associated pain relative to 90°
insertion. The microneedle, with varying bend angle, can be oriented for an insertion angle from 0° to 90°. Where the microneedle is close to or perpendicular to the skin at the entry site, a clear pathway for the substance to exit the skin is created upon withdrawal of the microneedle, resulting in leakage. Delivery of a complete dose of a substance under the stratum corneum is improved by the low acute angle insertion, especially when coupled with the downward facing beveled tip. The substance will more readily move down through the dermis. Moreover, with a low acute angle insertion, one has better control of the needle insertion depth.
Referring to FIG. 6A, there is shown a plot of insertion force of a needle versus penetration depth, illustrating the skin and needle behavior as described by the various labels. After the needle touches the skin, the skin is deformed until a first point of puncture, after which the needle slips. Subsequently, the needle deforms the second layer of skin until a second point of puncture, after which the needle slips again. Then the skin slides up the shaft of the needle. As the needle is pulled out, the skin is also deformed, as shown in the bottom portion of the graph.
Turning now to FIG. 6B-6I, a sequence of graphs illustrate the insertion force [N] versus penetration depths [mm] profiles for 100 pm (top graphs, FIGs. 6B-6E) and 570 p.m (bottom graphs, FIGs. 6F-61) needles that are at an angle of 15° to 90°
with respect to the surface of the skin and for needle insertion velocities of 0.1 and 1.0 mm/s. As is evident from the figures, the smaller needles have significantly smaller penetration forces. The figures also show that the velocity of needle insertion does not significantly affect the penetration forces. Finally, the figures show that needles inserted at smaller angles (for example, 15°) to the surface of the skin require smaller penetration forces. The peak insertion force for a 100 ~,m needle into the skin at a 9~° angle at a velocity of 1 mm/s is approximately 250 mN
(FIG. 6E), while the peak insertion force for a 100 p,m needle into the skin at a 15°
angle at a velocity of 1 mm/s is approximately 175 mN (FIG. 6C).
Thus, the microneedles 14 need not be parallel to the skin. They can be angled downward, for example, to facilitate penetration into the skin. The base 36 can be pushed against the skin so that portions of the skin will rise within access ports similar to the suction ports 60.
The rigid top section 50 of the reservoir 46 is made from stainless steel, glass, such as Type I or Type II high purity glass, or polymer, and the flexible membrane 48 is approximately 20 ~m to 300 Vim, preferably 100 ~.m, thick, and is made from a deformable elastopolymer such as silicone rubber or any other suitable flexible material. The reservoir 46 is typically filled with one or more pharmaceuticals for delivery to the patient, and then sealed.
In the embodiment shown in FIGs. 2A and 2B, the reservoir 46 is a single-chambered, hollow container with one rigid top section 50, and one deformable membrane 48. The reservoir 46 has a maximum fill thickness of approximately one to 5 mm, preferably about 2 mm, and a volume capacity approximately in the range of 100 ~1 to 5 ml In the device 10, the microneedles 14 are in contact with the pharmaceutical in the reservoir 46 when the ends 64 of the microneedles are inserted into the reservoir. There can be a semi-permeable membrane, filter, or valve placed between the reservoir 46 and the openings at the ends 64 of the microneedles. The membrane or filter can serve to purify the substance, or remove a selected material from the substance entering or leaving the reservoir. A membrane or filter can also contain a binding partner to the selected material, thereby capturing or trapping that material during the transport. The binding partner can be specific or nonspecific. A
valve is useful in preventing leakage as well as in precisely releasing a set amount of substance. The valve is also useful to prevent backflow of a collected fluid through the microneedles. In some embodiments, a microvalve is opened in each microneedle 14 to allow movement of fluid for delivery or collection. For example, the microvalve could be embedded in the microneedles 14 or be part of the reservoir 46. Alternatively, a non-permeable membrane, covering for example the end of the microneedle opening into the reservoir, can be breached to allow the fluid movement.
Rather than being a hollow chamber, in some embodiments the reservoir 46 can be a porous matrix, single or mufti-chambered, or any combination thereof.
The reservoir 46 can contain one or more chambers. Each chamber can be the same or may differ from any or all of the others. For example, a reservoir 46 can have one chamber that contains a reagent and into which fluid is drawn through the microneedles. A reaction might then occur in this first chamber, the results of which might trigger manual or automatic release of a substance from the second chamber through the microneedles into the skin.
The reservoir 46 is easily loaded with a substance to be delivered. Loading can occur before or after association of the reservoir 46 with the microneedles 14.
As mentioned earlier, the formulation can be one or more non-liquid drugs (for example, that have been dehydrated) that may be preloaded into the reservoir and then reconstituted before delivery. In some embodiments, the inside of the reservoir 46 is coated with a material prior to assembly of the reservoir. The coating can have one or more purposes, including, but not limited to, aiding flow so that the substance exiting or entering the reservoir moves smoothly and/or does not leave behind droplets, serving as a reactant used for detecting the presence or absence of a particular material in the fluid, and/or serving as a preservative.
When the transport device 10 is used to deliver drugs, the reservoir 46 stores one or more drugs in one or more chambers to be delivered to the target site.
The reservoir 46 can be filled with the desired drug through an opening situated opposite the placement of the microneedles 14. Alternatively, the desired drug can be drawn up into the reservoir 46 through the microneedles or the desired drug can be placed within the reservoir 46 when it is sealed.
When the transport device 10 is used to obtain samples from the patient, the reservoir 46 stores, in one or more chambers, one or more biological samples drawn from the patient. The device can include one or more elements directed at securing the sample within the reservoir during removal of the device from the skin.
These elements might include valves, flaps and the like.
Although in the embodiment illustrated in FIGS. 1 and 2 a vacuum seal is initially used to secure the device 10 to the skin, alternative mechanisms for securing the device 10 on the skin are available that include, but are not limited to, one or more straps, tape, glue, and/or bandages. The outer casings of the control unit 38, the drug vial 40, and the base portion 36 can be made of any stiff material, such as, but not limited to, stainless steel and other hard metals, plastics, woven or matted stiffened fibers, cardboard, and wood.
The actuator 52 disclosed herein facilitates pumping a drug through the microneedles into the skin or removing a sample from the patient. The actuator can be used to create a vacuum within the reservoir 46 before the device 10 it is placed against the skin. The actuator 52 provides controlled, programmable transport to and from the target site.
In the illustrated embodiment, the actuator 52 operates by an electrochemical reaction, in particular electrolysis of water (Hz0) that converts water into hydrogen (HZ) and oxygen (Oz) gas. There are two electrochemical reactions taking place:
oxidation is occurnng at the anode according to the reaction 2H20(1) ~Oz(g)+ 4 H+ (aq)+ 4e and reduction is occurring at the cathode according to the reaction 2Hz0(1) + 2e ~Hz(g)+ OH-To keep the numbers of electrons balance, the cathode reaction must take place twice as much as the anode reaction. Thus, if the cathode reaction is multiplied by two and the two reactions are added together, the total reaction becomes 6Hz0(1) + 4e ~2Hz(g)+ OZ(g) + 4 H+ (aq) + 40H-(aq) + 4e The H+ and OH- form HZO and cancel species that appear on both side of the equation. The overall net reaction therefore becomes 6Hz0(1) ~2Hz(g)+ Oz(g) Hence, three molecules ( 1 Oz, 2 Hz) are produced per 4 electrons. That is, the number of moles of gas created by electrochemical decomposition of water as described by the following equation is ng~ = ng~(e N,~ = 7.784 x 10-~ mol/C
where nK~ is the number of molecules of gas produced per electron put into the system, 3/4, a is the charge of one electron, and NA is Avogadro's number.
This conversion results in a large volume change of over, for example, three orders of magnitude, which is harnessed to expel the drug from the reservoir 46. When the conversion of water to hydrogen and oxygen occurs, the expansion compresses the flexible membrane 48, expelling the drug and any carriers or other compounds or solvents out of the reservoir 46 through the microneedles 14.
Referring in particular to FIG. 7A, there is shown the actuator 52 by itself for illustrative purposes. The chamber 59 contains, for example, 1 wl to 10 ml, preferably ,1 ~.1 to 1 ml, of water with 1 M of NazS04 or NaOH. To initiate the electrolytic process, a current, I, is applied to two electrodes 72 positioned within the chamber 59 of the actuator 52. Each electrode 72 can be solid or a mesh. The mesh configuration provides a larger surface area to initiate the decomposition process.
The electrodes can be made of stainless steel, platinum, or platinum/iridium gauze, such as Alfa Aesar #40934, or any other suitable material.
Referring to the graph depicted in FIG. 7B, there is shown a representative voltage to current relationship for the actuator or pump 52 with two 3 mm x 12 mm x 50 ~m thick stainless steel electrodes. FIG. 7C shows the voltage to current relationship for the actuator 52 with two 40 mm long Nichrome electrodes. Both FIGS. 7B and 7C show that no current is drawn, and therefore no gas is created, until the voltage reaches approximately 1.7 V. At this point, the current drawn by the pump begins to increase almost linearly until the current reaches approximately 115 mA, where it reaches steady state. The current versus voltage slopes for the linear region are different based on the electrode materials and configuration. For the pump 52 with stainless steel electrodes (FIG. 7B), the pump reaches steady current consumption at approximately 3. 8 V, while the pump with Nichrome electrodes (FIG. 7C) reaches steady current consumption at approximately 2.5 V.
Furthermore, at an operating current of about 10 mA, the operating voltage is about 2.5 V
and 1.79V for the stainless steel electrodes, and the Nichrome electrodes, respectively.
The electrolytic process can be easily stopped and if desired initiated again, and this process can be repeated to precisely control the expansion rate of the chamber and hence the drug delivery rate of the device 10.
The actuator 52 can be a micro-electric motor, such as, for example, Lorentz force or electrostatic motors, or operate by chemical or electrochemical reactions, contractile polymers, shape memory alloys, or any other suitable mechanism to facilitate the transport of the pharmaceutical. Alternatively or additionally, the actuator can include mechanical or organic members, such as micro-valves or permeable membranes, respectively, to further control transport rates. The actuator 52 can also be any other suitable micro-mechanism, such as motors, levers, pistons, solenoids, magnetic actuators, and the like, for controlling the motion of the flexible membrane 48 of the drug vial 40 to provide precise and controlled delivery of compounds and/or collection of body fluids.
In certain embodiments, the actuator 52 operates as a vapor generator.
Liquid water, for example, contained in the chamber 59 of the actuator 52 is heated with an on-board heater which causes the liquid to change to steam resulting in a significant increase in volume. In such embodiments, the volume of the liquid water is about 500 nl to 5 ~1. The temperature of vaporization of water is 100°C, and at that temperature the latent heat of vaporization is 2.25 kJ/kg. Thus for 1 p,l of liquid water, the steam volume becomes approximately 1.706 ml.
Alternatively, the top section 50 of the reservoir 46 can be formed from a conducting polymer, such as polypyrrol, which contracts (usually in one direction) under the application of a low voltage current. The conducting polymers act like human muscle, that is, they contract lengthwise. The force produced per area of these polymers is about 1 to 10 Mpa, which is about a factor of 10 greater than that of human muscles. The change in length of these polymers is about 2%.
Contraction of the conducting polymer forces the drug and any carriers or other compounds or solvents out of the reservoir 46.
When the device is used to collect samples, the actuator 52 functions as a reversible actuator to facilitate transport from the target area to the reservoir 46. For example, in the conducting polymer pump system, initial application of a low voltage current compresses the top section 50, emptying the reservoir 46.
While the reservoir is in its contracted state, the device 10 is applied to the target site. The voltage is then disrupted to allow the polymer to expand to its natural state.
Expansion of the reservoir 46 creates a vacuum inside the reservoir, which causes fluid to be drawn into the reservoir.
Another embodiment of the actuator 52 is a shape memory alloy or contractile polymer wrapped around a circle. The actuator forms a twist that is guided along a thread so that there is a linear (vertical) motion which places a force on the drug vial 40, thereby expelling the drug from the reservoir 46. The actuator is returned to its initial retracted state by one of many available means that includes but is not limited to shape memory alloys, springs, and super-elastic metal.
Recall, the vacuum pump 28 of the applicator 12 creates a suction to draw the skin in one direction into the openings 60 of the transport device 10, and the rotary actuator 30 provides an orthogonal direction of motion of the microneedles 14 to facilitate acute-angle insertion into the skin with the bent microneedles 14.
In other embodiments, these orthogonal motions may be accomplished by use of one or more actuators. For example, an actuator can be used to move the microneedles in a direction perpendicular to the skin surface so that the bent portion of the microneedle are parallel to and come into contact with the skin, with the microneedle tip opening facing the skin. The actuator continues to move the microneedles in the perpendicular direction, causing them to depress the skin under the microneedle, and resulting in the neighboring skin being above the level of the microneedle tips. The rotary actuator 30 then moves the microneedles 14 forward in the direction of the microneedle tip 62, parallel to the skin surface. The microneedle tips 62 contact the surface of the skin at the side of the depression formed by the initial perpendicular motion of the microneedle. The rotary actuator 30 continues to move the microneedles in the parallel direction causing the microneedles to penetrate the stratum corneum. When the microneedle tip 62 has reached the target site, the rotary actuator stops the motion. One or more actuators can be involved in each motion. Again, a stop signal can be generated using the impedance sensor system 32, discussed in detail below. Alternatively, there can be a hard mechanical stop or the insertion motion can be stopped after a defined distance of penetration, or a defined period of time of insertion. Removal of the microneedles 14 is accomplished in basically the reverse order.
Any of the foregoing embodiments, as well as any other applicable to the situation, could be synchronized with the impedance sensor 32, discussed in detail below, so that the drop in impedance, upon penetration through the stratum corneum, triggers the pumping action of the actuator 52, such as the electrolytic, chemical reaction, polymer contraction actuators, or an electric motor or any other actuators used in the device 10.
In certain embodiments, the device 10 is provided with contoured, drilled tunnels or guide sleeves through which the microneedles 14 are guided into the skin.
For safety and other reasons, the microneedles 14 can have caps or holsters covering the tips 62, as discussed previously, requiring additional movement of the device 10 as a first step to uncap the microneedles 14. The caps can be fastened to a moveable part within the device 10, and this part is moved by an actuator away from the microneedle tips to uncap the stationary microneedles 14. In another embodiment, the caps may be a free-standing structure that is manually removable prior to application, or the microneedles may penetrate through the protective caps prior to application.
In some embodiments, the transport device 10 and/or the applicator 12 is combined with an oscillator system, made from, for example, a piezoelectric crystal, to assist the insertion of the microneedles 14. The oscillator system can be an independent system, integrated with the actuators, or some combination thereof.
S Preferably, the microneedles are vibrated at 10 kHz in the direction of the penetration motion. A potential advantage of using such an oscillator system is that less force may be required to penetrate the skin.
As discussed above, the device 10 includes electrical sensors, such as the impedance sensor 32 which detects penetration of the stratum corneum. That is, the sensor 32 signals when the desired insertion of the microneedles 12 have been achieved. The determination of the location of the microneedle tips) within or through the stratum corneum allows for delivery of a complete, predetermined dose to the patient at a location amenable for absorption by the patient's body.
This is accomplished by measuring impedance of the tissue as the microneedles proceed through it. As the stratum corneum creates a high level of impedance, and the tissue beyond the stratum corneum only provides a relatively low level of impedance, impedance is monitored to determine when the microneedles have passed through the stratum corneum. At that point insertion may be stopped so as to avoid penetrating the skin layer containing nerves and capillaries.
In particular, as illustrated in FIG. 8A, a low voltage circuit is formed with two of the microneedles 14 acting as electrodes. Because the dry stratum corneum of the epidermis 90 acts as a capacitive barrier while the sub-epidermal layers 92 are well conducting, the impedance of the circuit drops as the microneedles pierce through the stratum corneum 90. The change in impedance is by one or more orders of magnitude and reliably indicates when the microneedles nave pierced through the stratum corneum 90. Furthermore, at less than 1 Volt, the voltage stimulus is not felt by the subject. Note that the microneedles 14 are electrically isolated from the base. An illustrative embodiment of a circuit diagram of the circuit used here is shown in FIG. 8B, where the Z,Qad represents the unknown impedance.
As an example, impedance measurements of pig skin is illustrated in FIG.
9A. The top portion 94 of the graph illustrates the measured impedance of pig skin over a frequency range before a microneedle penetrates the stratum corneum and the bottom portion 96 represents the measured impedance after the microneedle has penetrated the stratum corneum. As can be seen, the difference between the two portions 94 and 96 of the graph can be over three orders of magnitude. Turning also to FIG. 9B, there is shown a plot of impedance versus the perpendicular depth into the skin, which clearly illustrate that the penetration into the skin produces smaller impedances.
Rather than sweeping over a frequency range, the input signal of the impedance sensor 32 can be set at one frequency. The input signal can be a square wave generated by an embedded processor such as a TI-MSP430F149IPM, produced by Texas Instruments of Dallas, Texas. Certain characteristics of this chip are that it draws 35 pA when active, and less than 1 ~A in low power mode, and has a 64 pin PQFP package, a 1.8 to 3.6 V power supply, 8 analog to digital converters, 60 kbytes of flash memory, 2 kbytes of RAM, 2 16-bit timers, and an on-chip comparator.
1 S Alternatively, a processor such as a TI-MSP430F1 lOIPW can be used. This chip draws 35 ~.A when active, and less than 1 ~.A in low power mode, and includes a 20 pin TSSOP, 1.8 to 3.6 V power supply, 1 kbyte of flash memory, 128 bytes of RAM, and a 16-bit timer. Regardless which processor is used, the output signal can be pulse width modulated, and the impedance sensor 32 can be provided with a log transformer to compress the output signal to within the range of the analog to digital converter of the processor.
As mentioned earlier, in certain embodiments, a glucose sensor is associated with the transport device 10. In these embodiments, fluid is withdrawn from the patient through the microneedles 14 into one of a multiplicity of reservoir chambers.
The glucose sensor is at least partially in one of the chambers, where it can detect the concentration of glucose in the fluid. Information from the glucose sensor is read and interpreted by the operator of the device 10, for example, with the use of the display 22 of the applicator 12, who can then activate another chamber of the reservoir to deliver the appropriate amount of insulin to bring the glucose concentration to an appropriate Ievel. Alternatively, the procedure can be automated so that the glucose sensor reads the glucose concentration in the fluid, and, based on that concentration, sends a signal, such as an electronic signal, to the other chamber, "telling" that chamber whether or not to deliver insulin through a set of microneedles, and how much insulin to deliver.
In any of the above describe embodiments, one or more controllers such as a programmable microprocessor located in the transport device 10 andlor the applicator 12 can control and coordinate the actuators, pumps, sensors, and oscillators. For example, the controller can instruct the actuator 52 to pump a specified amount of drug into a patient at a specified time. The specified amount may be the full amount contained in the reservoir 46 or a partial amount.
Thus, the device is able to inject a partial or full amount of drug incrementally over a desired time period. One controller may control the operation of the applicator 12, while another controller controls the operation of the device 10. Alternatively, a single controller may control the operations of the applicator 12 and the device 10.
In any case, the applicator 12 and/or the device 10 can communicate with each other or 1 S with a central processor, for instance, using wireless communications capabilities provided with either or both the applicator 12 and the device 10.
The transdermal transport device 10 is not limited to the embodiments described above. For example, other embodiments of the transdermal transport device 10 are shown in FIGS. 10 and 1 l, where like reference numerals identify like features.
In the device 10 of FIG. 10, the microneedles 14 are again bent at about a 90°
angle. They are oriented so that there is a section that is parallel to the surface of the skin S and a section that is perpendicular to the base 36 of the device 10.
The microneedles 14 are soldered or attached in any suitable manner to a needle plate 100 that is able to turn, but not able to translate. In this embodiment, the microneedles 41 are not inserted into the drug vial 40 until just before delivery. The pump assembly or actuator 52 is pinned in place by three pins that slide in angled slots 101 as the inner portion of the device 10 is turned. For extra guidance and stability, the actuator 52 also rides on pins 102 in slots that are cut into the actuator 52.
The device 10 is first brought to the skin S by the applicator 12 (FIG. 1).
The electromagnet 26 in the applicator 12 turns the inside portion of the device 10, which causes the actuator 52 to translate down onto the ends 64 of the microneedles 14 as the needles are turned into the skin S while suction is being applied through the ports 14 to draw the skin S into the suction ports 60. Thus, the back ends 64 of the microneedles penetrate the vial 40 as the front ends penetrate the skin.
Alternatively, the back ends 64 of the microneedles can already be in the vial 40, while the front ends are provided with caps through which the needles penetrate, or are removed before inserting the needles into the skin. The drug in the reservoir 46 is then pumped through the microneedles 14 as the actuator 52 is activated.
The depth of insertion is controlled by hard stops 104 on the base plate 36.
The skin S is sucked into the suction ports 60 by vacuum up to these hard stops 104.
Since the microneedles 14 soldered into place at a specific depth, and the hard stops can be set to a desired distance from the plane of the needles, the depth of insertion can therefore be controlled.
The actuator 52 is mounted on top of the vial 40, with the flexible membrane 48 positioned between the two. The electrodes 72 are mounted inside the actuator 52, and the leads come out directly into a circuit board 106, which is mounted just above the top of the actuator 52. On the underside of the circuit board 106 are mounted the electronic components 43, and on the top side is mounted the battery or power source 45. The applicator 12 magnetically attaches to the battery 45 to hold and rotate the device 10, while electrical connection is made between the applicator 12 and the device 10 through the copper ring 42.
The device 10 of FIG. 10 has a height of about I S mm, while the device 10 of FIG. 11 has a lower profile with a height of about 7 mm. In FIG. 11, the microneedles 14 are mounted such that they always remain in the same plane of rotation. This helps reduce the overall height of the device 10, since open space between the ends 64 of the microneedles 14 and the drug vial 40 is not necessary.
The microneedles 14 can either be permanently affixed as part of the drug vial 40, or as a separate ring. If the microneedles I4 are mounted on a separate ring, the actuator 52 is rotated onto the back end 64 of the microneedles 14 before delivery.
Then, the entire actuator/microneedle assembly is rotated into the skin S.
The depth of insertion is controlled by the space 200 between the base 36 and the component 202 that couples the microneedles 14 to the vial 40. This component 202 could either be some sort of fluidic circuit or simply a ring that holds the microneedles 14 in place for insertion into the vial 40, or the microneedles may be part of the vial 40. Vacuum suction would still be used to draw the skin into the ports 60 before insertion of the microneedles 14.
The actuator SZ is mounted as a ring around the vial 40. The top portion 204 of the actuator 52 is still above the vial 40, and the flexible membrane 48 is located between the top portion 204 and the vial 40. However, most of the actuator 52 is placed round the outside of the vial 40. This helps reduce the overall height of the device 10. The electrodes can be mounted as ring electrodes directly from the circuit board 106, which can also function as the top of the actuator 52. The battery 45 and 1 S the electronic components 43 are all mounted on the top of the circuit board 106.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
For example, the actuator or pump arrangements, such as the electrolytic actuator, can be used in other types of transdermal transport devices, as well, such as the devices described in the U.S. Application No. 10/238,844, filed September 9, 2002, by Angel and Hunter, the entire contents of which are incorporated herein by reference.
rotary actuator can be used to move the second end of the needle in the plane.
The actuator can include a vapor generator, or alternatively, the actuator operates by an electrochemical process, or is a conductive polymer.
In some embodiments, the device includes an oscillator which causes the second end of the needle to vibrate along its length to reduce the force required to drive the needle into the body. The oscillator can be a piezoelectric crystal which generates the vibration of the needles.
In certain embodiments, the device includes a sensor to monitor the status of a patient, for example, the glucose concentration of the patient. In such implementations, the formulation can be insulin pumped into the patient, with the amount of insulin pumped being based on the glucose concentration.
In another embodiment, the second end of the needle has tip end that is slanted and defines an opening from which the formulation is dispensed to control the direction of diffusion of the formulation into the body. The tip can be slanted between about 10° to 60°.
The second end of the needle can have a plurality of openings along its length such that the formulation is dispensed from and drawn through the plurality of openings.
There can be one to 20 openings that are spaced apart between about 100 ~,m to In yet other embodiments, the device includes a controller which directs the actuator to pump a desired amount of the formulation. The desired amount is dependent on input specifics of the body. The desired amount can be dispensed over a particular time period, lasting, for example, from 1 sec to 10 days. The desired amount of formulation can be dispensed incrementally over time. The body can be a human patient, such that the desired amount of the formulation is a sample collected from the patient drawn into the reservoir over a particular time period. The device can include a base unit that contains the needle, and a control unit that contains the controller. The base unit and the control unit can be separate connectable units.
Other embodiments are directed to methods of using the transdermal transport device described above.
Some embodiments of the invention may have one or more of the following advantages. The microneedle transport device disclosed here further presents the advantages of low manufacturing costs, and high efficiency. Particularly in regards to ease of use, the automated/mechanical system of the microneedle device reduces the error and uncertainty usually introduced by manual application. Very little (if any) pain, local damage, bleeding, or risk of infection is caused by the microneedles.
Additionally, no special training or expertise is required to use the microneedle transport device. The device may further be adapted for disposable single-use, partial or full reuse, short or long-term use, or continuous or intermittent transport, or some combination thereof. The device is able to deliver a range of drug types and viscosities with variable delivery. For example, a significant amount of drug can be delivered in the beginning followed by maintenance dosing. The delivery can be periodic, for example, every hour, or can be on demand. The device provides for controllable and precise drug delivery to a location below the outer surface of the skin of the patient. That is, any desirable delivery profile can be set, for example, constant or intermittent, for delivery to a desired location. The device can provide on-demand delivery, for example, by pushing a button, when a patient desires some sort of pain control.
Since a precise amount of volume of drug can be delivered, there is a low volume of wasted drug. In addition to delivering a precise volume of drug with a variety of delivery profiles, the device is able to deliver a range of drugs.
For example, the formulation may be a liquid, or a non-liquid that is reconstituted at delivery, or some combination thereof.
The device provides reduced pain as compared to traditional hypodermic injections, with minimal air injected under the skin. A user of the device is able to verify drug, dosing, expiration, etc. with, for example, a computer server via the Internet. The impedance testing provides a convenient way of determining the depth of penetration of the needles. The device is small and portable, and the geometry of the device makes it comfortable to wear. The device is inexpensive and easy to use, and, hence, increases patient compliance. In addition, since the microneedles are protected within the base portion, exposure to contamination and/or accidental contact with a patient or medical clinician is eliminated or minimized.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
FIG. 1 is a side schematic view of an applicator with a transdermal transport device in accordance with the invention.
FIG. 2A is a cross-sectional view of the transdermal transport device shown in FIG. 1.
FIG. 2B is a top view of the transdermal transport device shown in FIG. 1.
FIG. 2C is a bottom view of the transdermal transport device shown in FIG.
1.
FIG. 2D is a close-up view of a suction port shown in FIG. 2C illustrating a microneedle in retracted and protracted states.
FIG. 3 is a close-up view of a tip of a microneedle of the transdermal transport device shown in FIG. 1 shown penetrating the skin of a patient and dispensing a drug into the patient.
FIG. 4 is a close-up view of the tip of a microneedle of the transdermal transport device shown in FIG. 1.
FIG. 5 is a side view of an alternative embodiment of a microneedle in accordance with the invention.
FIG. 6A is a graph of the insertion force of a microneedle versus the penetration depth of the microneedle.
FIG. 6B-6I is a sequence of graphs of the insertion force of a microneedle versus the penetration depth of the microneedle for different diameter needles.
FIG. 7A is a view of an actuator of the transdermal transport device shown in FIG. 2A.
FIG. 7B is a graph of the voltage requirements of the actuator shown in FIG.
7A with stainless steel electrodes.
FIG. 7C is a graph of the voltage requirements of the actuator shown in FIG.
7A with Nichrome electrodes.
FIG. 8A is schematic of a circuit formed with electrodes of an impedance sensor of the transdermal transport device shown in FIG. 1 and the skin of a patient.
FIG. 8B is a schematic diagram of a circuit used for the impedance sensor in accordance with the invention.
FIG. 9A is a graph of the magnitude of the impedance measured by the impedance sensor of FIG. 8A versus frequency.
FIG. 9B is a graph of the impedance versus the penetration depth.
FIG. 10 is a cross-sectional view of an alternative embodiment of the transdermal transport device.
FIG. 11 is a cross-sectional view of yet another alternative embodiment of the transdermal transport device.
DETAILED DESCRIPTION OF THE INVENTION
A description of preferred embodiments of the invention follows.
Referring to FIG. 1, there is shown a transdermal transport device 10 mounted to a coupling 11 of an applicator 12 which is used to attach the transport device 10 to the skin of a biological body, such as a human patient.
Furthermore, the applicator 12 activates the device 10 to initiate the transport process before being disengaged from the device.
The device 10 includes an array of microneedles 14 for piercing the outer layers of skin of the patient and for delivering a formulation of an active principle such as pharmaceuticals through the skin to provide accurate delivery of the _g_ pharmaceuticals to the patient. Moreover, because of the shape and size of the needles and the minimal depth of penetration of the needles, contact between the needles and the nerve endings beneath the outer layer of the skin is minimized so that pain is reduced or absent in the patient. The pharmaceutical may be a liquid formulation, or it may be one or more non-liquid drugs that are reconstituted just before delivery.
The applicator 12 is powered by a set of batteries 16 and controlled by an embedded processor 18 positioned within a housing 20 which holds various other internal components of the applicator. A display 22, such as an LCD, mounted on top of the housing 20 communicates to a user the operating parameters of the transport device 10 and the applicator 12. The applicator 12 is able to communicate with a mother unit such as a PC and/or through the Internet with a communication card 24. In some embodiments, the communication card is an ethernet card.
Additionally or alternatively, the communication card can be a Bluetooth card which provides wireless communication capabilities.
The transport device 10 is mounted to the applicator 12 with an electromagnet 26. To disengage the transport device 10 from the applicator, voltage to the electromagnet is simply turned off to break the magnetic coupling between the top of the transport device 10 and the electromagnet 26. The applicator 12 also includes a vacuum pump 28 which draws a vacuum through a suction port 41 (FIG.
2A) to create a suction between suction ports 60 (FIG. 2A) of the transport device 10 and the skin of the patient to attach the device 10 to the skin. The microneedles 14 are bent at about a 90° angle about 1/3 of the distance from the tip 62 to the other end 64 (FIG. 2A) of each microneedle. Accordingly, as a rotary actuator 30, such as a stepper motor, shape memory alloy, contractile polymer, rotary solenoid, or any other suitable rotary actuator, rotates the transport device 10 and thus moves the mirconeedles 14, they penetrate laterally into the skin since the suction produced by the vacuum pump 28 also draws the skin into the suction ports 60 above a plane defined by the tip portions 62 of the microneedles. An impedance sensor 32 is used to indicate when the microneedles have sufficiently penetrated into the skin.
A
piezoelectric or a speaker 34 is also used to provide audible, perhaps verbal, indications to the user. The operation of the transport device 10 and applicator 12 will be described below in greater detail.
Referring now to FIGS. 2A and 2B, in addition to a base portion 36 which holds the microneedles 14, the transport device 10 includes a control unit 38 and a drug vial 40. The control unit 38 is provided with electrical connections 42 which facilitate communication between the device 10 and the applicator 12, control electronics 43, and various sensors 44 that measure, for example, impedance, pressure, temperature, injection flow rate, as well as other sensors. Any of these sensors can also be located in the applicator 12, such as a pressure sensor 37. The control unit 38 also includes a power source 45 such as a supercapacitor and batteries which provide power to the device 10.
The drug vial 40 includes a drug chamber or reservoir 46 defined by a flexible membrane 48 and a rigid top section 50. Located above the drug vial 40 in the control unit 38 is an actuator 52. The actuator 52 is provided with a rigid base 54 that is joined to a cap 56 with a flexible bellow 58, or any other suitable expanding material, defining a chamber 59. As illustrated in FIGS. 2C and 2D, the suction ports 60 are located at the bottom of the base portion 36 to provide access for the tips 62 of the microneedles 14 to the skin.
In use, the applicator 12 is turned on by the user, such as a medical clinician, to activate the electromagnet 26 to attach the device 10 to the applicator 12.
The user then delivers the device 10 to the skin. Next, the vacuum pump 28 creates a vacuum seal through the vacuum ports 60 with the skin to hold the device 10 in place, and also to make the skin more accessible to the microneedles 14 as discussed above.
Referring to FIG. 3, the vacuum pump 28 draws a suction, indicated by the arrows A, in the ports 60 to bring the skin up to the necessary height in the ports.
The rotary actuator 30 then rotates and hence moves the microneedles 14 towards the skin in a direction at or about right angles to the direction of movement of the skin as it is sucked into the openings 60. Once the microneedles 14 contact the skin, they continue to move in the same direction approximately SO ~m to several mm into the skin, thereby penetrating the sidewall of the raised skin as illustrated in FIG. 4.
In one embodiment, the penetration depth is approximately 200 Vim. The extent of movement in this direction is dictated by the depth of the stratum corneum at the site where the microneedles 14 penetrate the skin. As stratum corneum depth varies, the applicator 12 uses the impedance sensor 32 to determine when the stratum corneum has been transversed. The impedance sensor 32 measures impedance of electric current flow between two of the microneedles 14. Impedance is high in the stratum corneum, and drops dramatically in the portion of the dermis just below the stratum corneum (see, e.g., FIG. 9B which shows a drop of approximately three orders of magnitude). The sensor 32 reads the change in impedance as the microneedles 14 penetrate into the skin, and movement is stopped when the impedance drops by an order of magnitude. Additionally or alternatively, there can be a hard mechanical stop, for example, the top of the ports 60, that prevents the microneedles from penetrating too deeply.
At this point, the vacuum pump 28 and the electromagnet 26 are de-activated to disengage the device 10 from the applicator 12. The vacuum seal between the device 10 and the skin is no longer needed to secure the device to the skin since the device 10 is now attached to the skin with the microneedles 14 The control unit 38 of the device 10 then activates the actuator 52 which operates in the illustrated embodiment by an electrolytic process to cause the volume within the chamber 59 to increase and hence forcing the cap 56 against the rigid top section 50 of the drug vial 40, thereby pushing the drug vial 40 downwards.
Consequently, the flexible membrane 48 is pushed against a bowed section 68 of a base plate 39, while the ends 64 of the microneedles 14 pierce through the membrane 48 and into the reservoir 46. Compression of the membrane 48 into the reservoir 46 expels the pharmaceutical through hollow pathways or bores of the microneedles into the skin. Thus, the device is able to deliver a pharmaceutical to a precise location just below the stratum corneum of the skin, as indicated by the letter B in FIG. 3.
Once the correct dose of the pharmaceutical is delivered, the device 10 is re-attached to the applicator 12 and the rotary actuator 30 moves the microneedles out of the skin to disengage the device 10 from the patient. Typically, the base portion 36 and the drug vial 40 are discarded, while the control unit 38 is re-used.
The device 10 is used to deliver precise amounts of drugs as needed by a patient.
Information relating to the patient can be relayed through an associated computer to the device 10 and the applicator 12 via the communication card 24.
The same device 10 can be used for collecting fluid, such as interstitial fluid, from the dermis. For collection to occur, the reservoir 46 must first be compressed.
This is accomplished by moving the drug vial 40 downward with the actuator SO
such that the membrane 48 of the reservoir 46 is compressed to expel any air in the reservoir 46. Upon penetration of the microneedles into the skin, the expansion chamber 59 of the actuator 52 is contracted to allow the drug vial 40 to rise which creates a vacuum inside the reservoir 46 to draw fluid through the microneedles into the reservoir 46.
Thus, the actuator 52 acts as a pump which facilitates pumping a drug through the microneedles into the skin or collecting a sample from the patient. The actuator 52 can be used to create a vacuum within the reservoir 46 before the device 10 is placed against the skin. In sum, the actuator 52 provides controlled, programmable transport to and from the target site.
The various features of the transport device 10 and the applicator 12 will now be described in greater detail.
In the present application, the term "microneedle" is intended to be construed as singular or plural, unless specifically modified by a term indicating the number of microneedles. Microneedles disclosed herein may be porous or non-porous, uniform or of varying diameters or cross-sectional geometries, or some combination thereof.
Hollow microneedles with uniform diameter are sometimes referred to as microtubes. As used herein, the term "microneedle" refers to both microtubes and any other kind of microneedle as described previously. Additionally, microneedles may also have openings at either or both ends, as well as, on the side-walls at various and/or multiple positions along the length, or any combination thereof.
Further, either or both ends of the microneedle may be flat, tapered to a point, rounded, or beveled from one or more sides, as described below.
As shown in FIG. 4, the tip 62 has an opening 71 and is cut at an angle, a, of approximately 10° to 60°, to provide a slanted surface 66a. This surface 66a and/or the outer surface 66b can be beveled. The illustrated embodiment has four microneedles 14, but there can be ten microneedles or more. The microneedles are metal welded or soldered to the base plate 39, made from, for example, stainless steel, of the base portion 36, and the bellows 58 is formed of a polymer and is ultrasonic welded to the base 54 and the cap 56 of the actuator 52, or the bellow can be permanently attached to either the control unit 38 or the drug vial 40.
Alternatively, these parts may be fitted together via a thermal seal or any other suitable technique for forming a fluid-tight seal. Note that the device 10 is in use or not, the microneedles 14 are always contained within the base portion 36 and never extend outside of the suction ports 60 beyond the bottom of the base portion 36.
This minimizes or eliminates contamination of the microneedles and accidental contact between the needles and a patient or medical clinician.
1 S The beveled surfaces 66a and/or 66b of the tip 62 has many advantages. It reduces the trauma to the skin; it further reduces any pain felt by the subject; it prevents coring of the tissue into the microneedle; and it decreases the amount of force required for penetration into the skin. Particularly, in regards to coring, sharp tipped microneedles having a small inner diameter are less likely to accumulate tissue within the hollow opening, thereby avoiding transport blockage. In the above embodiment, both ends of each microneedle 14 are sharpened: one end for insertion into the skin, and the other end for insertion through membrane 48 into the reservoir 46.
In certain embodiments, as illustrated in FIG. 5, the microneedles 14 can have holes 73 on the side-walls at various andlor multiple positions along the length through which fluid can be transmitted, combined with the openings 71 (FIG. 4) or with solid tips 75. There can be from one to 20 or more holes 73. The spacing between the holes is approximately in the range of 100 p.m to 2 mm.
The microneedles 14 may be manufactured from a variety of materials and by a variety of methods. Representative materials include metals, ceramics, semiconductors, organics, biodegradable and non-biodegradable polymers, glass, quartz, and various composites. Representative methods include micro-fabrication techniques. In the above illustrated embodiment, the microneedles 14 are made of medical grade stainless steel, such as 304 stainless steel. Stainless steel microneedles are advantageous because they are durable, semi-flexible, and have the mechanical strength to endure insertion into the stratum corneum. They can be cut from readily available, relatively inexpensive commercial stock via a chemical saw, or any suitable technique, to the desired dimensions, and ground to the desired tip geometry.
The microneedles 14 have an inner diameter of about 10 p,m to 100 p,m, an outer diameter of 30 pm to 250 pm, and a length of approximately 5 mm to 10 mm.
In the above illustrated embodiment, each of the microneedles has an inner diameter of 54 Vim, and an outer diameter of 108 Vim. Other embodiments use microneedles with an inner diameter of about 100 pm and outer diameter of about 175 pm.
The microneedles 14 can also be coated on the outside, the inside, or both.
Coatings can cover part or all of either or both surfaces. Coatings can be selected from, but are not limited to, the group consisting of lubricants, chemical or biological reaction elements, and preservatives.
The microneedles may be made of one or more rows of microneedles of uniform or varying dimensions and geometries, with uniform or varying spacing, at uniform or varying projection angles, and any combination thereof. In the embodiment above, the set of microneedles form a circular array of four microneedles. The array has a radius of approximately 5 mm to 20 mm. In the illustrated embodiment, the radius is about 12 mm. In another embodiment, the set may include more than one circular array of microneedles. In yet another embodiment, the microneedles are arranged in an X by Y array, where X may or may not equal Y.
Additionally, as described above, the microneedle is bent, at approximately a 90° angle. As shown in FIG. 3, the bend of around 90° is positioned such that the segment from the bend to the tip 62 of the microneedle is long enough to penetrate through the stratum corneum. However, the angle, curvature, and location of the bend in the microneedle, as well as the orientation of the microneedle with respect to the device 10, can vary. For example, the bend angle may be 90° or more or less, but typically less than 180°.
In the bent microneedle embodiment, the bevel side 66a faces away from the bend and towards the skin surface, prior to insertion of the microneedle into the skin, and continues to face away from the rest of the device once it is inserted.
Penetration occurs at "acute-angle insertion" of the microneedle. The angle of insertion, p, (FIG. 3) is the angle formed by the skin surface and the microneedle 14, with the vertex of the angle at the point of contact between the microneedle and the skin surface. Acute-angle insertion reduces the associated pain relative to 90°
insertion. The microneedle, with varying bend angle, can be oriented for an insertion angle from 0° to 90°. Where the microneedle is close to or perpendicular to the skin at the entry site, a clear pathway for the substance to exit the skin is created upon withdrawal of the microneedle, resulting in leakage. Delivery of a complete dose of a substance under the stratum corneum is improved by the low acute angle insertion, especially when coupled with the downward facing beveled tip. The substance will more readily move down through the dermis. Moreover, with a low acute angle insertion, one has better control of the needle insertion depth.
Referring to FIG. 6A, there is shown a plot of insertion force of a needle versus penetration depth, illustrating the skin and needle behavior as described by the various labels. After the needle touches the skin, the skin is deformed until a first point of puncture, after which the needle slips. Subsequently, the needle deforms the second layer of skin until a second point of puncture, after which the needle slips again. Then the skin slides up the shaft of the needle. As the needle is pulled out, the skin is also deformed, as shown in the bottom portion of the graph.
Turning now to FIG. 6B-6I, a sequence of graphs illustrate the insertion force [N] versus penetration depths [mm] profiles for 100 pm (top graphs, FIGs. 6B-6E) and 570 p.m (bottom graphs, FIGs. 6F-61) needles that are at an angle of 15° to 90°
with respect to the surface of the skin and for needle insertion velocities of 0.1 and 1.0 mm/s. As is evident from the figures, the smaller needles have significantly smaller penetration forces. The figures also show that the velocity of needle insertion does not significantly affect the penetration forces. Finally, the figures show that needles inserted at smaller angles (for example, 15°) to the surface of the skin require smaller penetration forces. The peak insertion force for a 100 ~,m needle into the skin at a 9~° angle at a velocity of 1 mm/s is approximately 250 mN
(FIG. 6E), while the peak insertion force for a 100 p,m needle into the skin at a 15°
angle at a velocity of 1 mm/s is approximately 175 mN (FIG. 6C).
Thus, the microneedles 14 need not be parallel to the skin. They can be angled downward, for example, to facilitate penetration into the skin. The base 36 can be pushed against the skin so that portions of the skin will rise within access ports similar to the suction ports 60.
The rigid top section 50 of the reservoir 46 is made from stainless steel, glass, such as Type I or Type II high purity glass, or polymer, and the flexible membrane 48 is approximately 20 ~m to 300 Vim, preferably 100 ~.m, thick, and is made from a deformable elastopolymer such as silicone rubber or any other suitable flexible material. The reservoir 46 is typically filled with one or more pharmaceuticals for delivery to the patient, and then sealed.
In the embodiment shown in FIGs. 2A and 2B, the reservoir 46 is a single-chambered, hollow container with one rigid top section 50, and one deformable membrane 48. The reservoir 46 has a maximum fill thickness of approximately one to 5 mm, preferably about 2 mm, and a volume capacity approximately in the range of 100 ~1 to 5 ml In the device 10, the microneedles 14 are in contact with the pharmaceutical in the reservoir 46 when the ends 64 of the microneedles are inserted into the reservoir. There can be a semi-permeable membrane, filter, or valve placed between the reservoir 46 and the openings at the ends 64 of the microneedles. The membrane or filter can serve to purify the substance, or remove a selected material from the substance entering or leaving the reservoir. A membrane or filter can also contain a binding partner to the selected material, thereby capturing or trapping that material during the transport. The binding partner can be specific or nonspecific. A
valve is useful in preventing leakage as well as in precisely releasing a set amount of substance. The valve is also useful to prevent backflow of a collected fluid through the microneedles. In some embodiments, a microvalve is opened in each microneedle 14 to allow movement of fluid for delivery or collection. For example, the microvalve could be embedded in the microneedles 14 or be part of the reservoir 46. Alternatively, a non-permeable membrane, covering for example the end of the microneedle opening into the reservoir, can be breached to allow the fluid movement.
Rather than being a hollow chamber, in some embodiments the reservoir 46 can be a porous matrix, single or mufti-chambered, or any combination thereof.
The reservoir 46 can contain one or more chambers. Each chamber can be the same or may differ from any or all of the others. For example, a reservoir 46 can have one chamber that contains a reagent and into which fluid is drawn through the microneedles. A reaction might then occur in this first chamber, the results of which might trigger manual or automatic release of a substance from the second chamber through the microneedles into the skin.
The reservoir 46 is easily loaded with a substance to be delivered. Loading can occur before or after association of the reservoir 46 with the microneedles 14.
As mentioned earlier, the formulation can be one or more non-liquid drugs (for example, that have been dehydrated) that may be preloaded into the reservoir and then reconstituted before delivery. In some embodiments, the inside of the reservoir 46 is coated with a material prior to assembly of the reservoir. The coating can have one or more purposes, including, but not limited to, aiding flow so that the substance exiting or entering the reservoir moves smoothly and/or does not leave behind droplets, serving as a reactant used for detecting the presence or absence of a particular material in the fluid, and/or serving as a preservative.
When the transport device 10 is used to deliver drugs, the reservoir 46 stores one or more drugs in one or more chambers to be delivered to the target site.
The reservoir 46 can be filled with the desired drug through an opening situated opposite the placement of the microneedles 14. Alternatively, the desired drug can be drawn up into the reservoir 46 through the microneedles or the desired drug can be placed within the reservoir 46 when it is sealed.
When the transport device 10 is used to obtain samples from the patient, the reservoir 46 stores, in one or more chambers, one or more biological samples drawn from the patient. The device can include one or more elements directed at securing the sample within the reservoir during removal of the device from the skin.
These elements might include valves, flaps and the like.
Although in the embodiment illustrated in FIGS. 1 and 2 a vacuum seal is initially used to secure the device 10 to the skin, alternative mechanisms for securing the device 10 on the skin are available that include, but are not limited to, one or more straps, tape, glue, and/or bandages. The outer casings of the control unit 38, the drug vial 40, and the base portion 36 can be made of any stiff material, such as, but not limited to, stainless steel and other hard metals, plastics, woven or matted stiffened fibers, cardboard, and wood.
The actuator 52 disclosed herein facilitates pumping a drug through the microneedles into the skin or removing a sample from the patient. The actuator can be used to create a vacuum within the reservoir 46 before the device 10 it is placed against the skin. The actuator 52 provides controlled, programmable transport to and from the target site.
In the illustrated embodiment, the actuator 52 operates by an electrochemical reaction, in particular electrolysis of water (Hz0) that converts water into hydrogen (HZ) and oxygen (Oz) gas. There are two electrochemical reactions taking place:
oxidation is occurnng at the anode according to the reaction 2H20(1) ~Oz(g)+ 4 H+ (aq)+ 4e and reduction is occurring at the cathode according to the reaction 2Hz0(1) + 2e ~Hz(g)+ OH-To keep the numbers of electrons balance, the cathode reaction must take place twice as much as the anode reaction. Thus, if the cathode reaction is multiplied by two and the two reactions are added together, the total reaction becomes 6Hz0(1) + 4e ~2Hz(g)+ OZ(g) + 4 H+ (aq) + 40H-(aq) + 4e The H+ and OH- form HZO and cancel species that appear on both side of the equation. The overall net reaction therefore becomes 6Hz0(1) ~2Hz(g)+ Oz(g) Hence, three molecules ( 1 Oz, 2 Hz) are produced per 4 electrons. That is, the number of moles of gas created by electrochemical decomposition of water as described by the following equation is ng~ = ng~(e N,~ = 7.784 x 10-~ mol/C
where nK~ is the number of molecules of gas produced per electron put into the system, 3/4, a is the charge of one electron, and NA is Avogadro's number.
This conversion results in a large volume change of over, for example, three orders of magnitude, which is harnessed to expel the drug from the reservoir 46. When the conversion of water to hydrogen and oxygen occurs, the expansion compresses the flexible membrane 48, expelling the drug and any carriers or other compounds or solvents out of the reservoir 46 through the microneedles 14.
Referring in particular to FIG. 7A, there is shown the actuator 52 by itself for illustrative purposes. The chamber 59 contains, for example, 1 wl to 10 ml, preferably ,1 ~.1 to 1 ml, of water with 1 M of NazS04 or NaOH. To initiate the electrolytic process, a current, I, is applied to two electrodes 72 positioned within the chamber 59 of the actuator 52. Each electrode 72 can be solid or a mesh. The mesh configuration provides a larger surface area to initiate the decomposition process.
The electrodes can be made of stainless steel, platinum, or platinum/iridium gauze, such as Alfa Aesar #40934, or any other suitable material.
Referring to the graph depicted in FIG. 7B, there is shown a representative voltage to current relationship for the actuator or pump 52 with two 3 mm x 12 mm x 50 ~m thick stainless steel electrodes. FIG. 7C shows the voltage to current relationship for the actuator 52 with two 40 mm long Nichrome electrodes. Both FIGS. 7B and 7C show that no current is drawn, and therefore no gas is created, until the voltage reaches approximately 1.7 V. At this point, the current drawn by the pump begins to increase almost linearly until the current reaches approximately 115 mA, where it reaches steady state. The current versus voltage slopes for the linear region are different based on the electrode materials and configuration. For the pump 52 with stainless steel electrodes (FIG. 7B), the pump reaches steady current consumption at approximately 3. 8 V, while the pump with Nichrome electrodes (FIG. 7C) reaches steady current consumption at approximately 2.5 V.
Furthermore, at an operating current of about 10 mA, the operating voltage is about 2.5 V
and 1.79V for the stainless steel electrodes, and the Nichrome electrodes, respectively.
The electrolytic process can be easily stopped and if desired initiated again, and this process can be repeated to precisely control the expansion rate of the chamber and hence the drug delivery rate of the device 10.
The actuator 52 can be a micro-electric motor, such as, for example, Lorentz force or electrostatic motors, or operate by chemical or electrochemical reactions, contractile polymers, shape memory alloys, or any other suitable mechanism to facilitate the transport of the pharmaceutical. Alternatively or additionally, the actuator can include mechanical or organic members, such as micro-valves or permeable membranes, respectively, to further control transport rates. The actuator 52 can also be any other suitable micro-mechanism, such as motors, levers, pistons, solenoids, magnetic actuators, and the like, for controlling the motion of the flexible membrane 48 of the drug vial 40 to provide precise and controlled delivery of compounds and/or collection of body fluids.
In certain embodiments, the actuator 52 operates as a vapor generator.
Liquid water, for example, contained in the chamber 59 of the actuator 52 is heated with an on-board heater which causes the liquid to change to steam resulting in a significant increase in volume. In such embodiments, the volume of the liquid water is about 500 nl to 5 ~1. The temperature of vaporization of water is 100°C, and at that temperature the latent heat of vaporization is 2.25 kJ/kg. Thus for 1 p,l of liquid water, the steam volume becomes approximately 1.706 ml.
Alternatively, the top section 50 of the reservoir 46 can be formed from a conducting polymer, such as polypyrrol, which contracts (usually in one direction) under the application of a low voltage current. The conducting polymers act like human muscle, that is, they contract lengthwise. The force produced per area of these polymers is about 1 to 10 Mpa, which is about a factor of 10 greater than that of human muscles. The change in length of these polymers is about 2%.
Contraction of the conducting polymer forces the drug and any carriers or other compounds or solvents out of the reservoir 46.
When the device is used to collect samples, the actuator 52 functions as a reversible actuator to facilitate transport from the target area to the reservoir 46. For example, in the conducting polymer pump system, initial application of a low voltage current compresses the top section 50, emptying the reservoir 46.
While the reservoir is in its contracted state, the device 10 is applied to the target site. The voltage is then disrupted to allow the polymer to expand to its natural state.
Expansion of the reservoir 46 creates a vacuum inside the reservoir, which causes fluid to be drawn into the reservoir.
Another embodiment of the actuator 52 is a shape memory alloy or contractile polymer wrapped around a circle. The actuator forms a twist that is guided along a thread so that there is a linear (vertical) motion which places a force on the drug vial 40, thereby expelling the drug from the reservoir 46. The actuator is returned to its initial retracted state by one of many available means that includes but is not limited to shape memory alloys, springs, and super-elastic metal.
Recall, the vacuum pump 28 of the applicator 12 creates a suction to draw the skin in one direction into the openings 60 of the transport device 10, and the rotary actuator 30 provides an orthogonal direction of motion of the microneedles 14 to facilitate acute-angle insertion into the skin with the bent microneedles 14.
In other embodiments, these orthogonal motions may be accomplished by use of one or more actuators. For example, an actuator can be used to move the microneedles in a direction perpendicular to the skin surface so that the bent portion of the microneedle are parallel to and come into contact with the skin, with the microneedle tip opening facing the skin. The actuator continues to move the microneedles in the perpendicular direction, causing them to depress the skin under the microneedle, and resulting in the neighboring skin being above the level of the microneedle tips. The rotary actuator 30 then moves the microneedles 14 forward in the direction of the microneedle tip 62, parallel to the skin surface. The microneedle tips 62 contact the surface of the skin at the side of the depression formed by the initial perpendicular motion of the microneedle. The rotary actuator 30 continues to move the microneedles in the parallel direction causing the microneedles to penetrate the stratum corneum. When the microneedle tip 62 has reached the target site, the rotary actuator stops the motion. One or more actuators can be involved in each motion. Again, a stop signal can be generated using the impedance sensor system 32, discussed in detail below. Alternatively, there can be a hard mechanical stop or the insertion motion can be stopped after a defined distance of penetration, or a defined period of time of insertion. Removal of the microneedles 14 is accomplished in basically the reverse order.
Any of the foregoing embodiments, as well as any other applicable to the situation, could be synchronized with the impedance sensor 32, discussed in detail below, so that the drop in impedance, upon penetration through the stratum corneum, triggers the pumping action of the actuator 52, such as the electrolytic, chemical reaction, polymer contraction actuators, or an electric motor or any other actuators used in the device 10.
In certain embodiments, the device 10 is provided with contoured, drilled tunnels or guide sleeves through which the microneedles 14 are guided into the skin.
For safety and other reasons, the microneedles 14 can have caps or holsters covering the tips 62, as discussed previously, requiring additional movement of the device 10 as a first step to uncap the microneedles 14. The caps can be fastened to a moveable part within the device 10, and this part is moved by an actuator away from the microneedle tips to uncap the stationary microneedles 14. In another embodiment, the caps may be a free-standing structure that is manually removable prior to application, or the microneedles may penetrate through the protective caps prior to application.
In some embodiments, the transport device 10 and/or the applicator 12 is combined with an oscillator system, made from, for example, a piezoelectric crystal, to assist the insertion of the microneedles 14. The oscillator system can be an independent system, integrated with the actuators, or some combination thereof.
S Preferably, the microneedles are vibrated at 10 kHz in the direction of the penetration motion. A potential advantage of using such an oscillator system is that less force may be required to penetrate the skin.
As discussed above, the device 10 includes electrical sensors, such as the impedance sensor 32 which detects penetration of the stratum corneum. That is, the sensor 32 signals when the desired insertion of the microneedles 12 have been achieved. The determination of the location of the microneedle tips) within or through the stratum corneum allows for delivery of a complete, predetermined dose to the patient at a location amenable for absorption by the patient's body.
This is accomplished by measuring impedance of the tissue as the microneedles proceed through it. As the stratum corneum creates a high level of impedance, and the tissue beyond the stratum corneum only provides a relatively low level of impedance, impedance is monitored to determine when the microneedles have passed through the stratum corneum. At that point insertion may be stopped so as to avoid penetrating the skin layer containing nerves and capillaries.
In particular, as illustrated in FIG. 8A, a low voltage circuit is formed with two of the microneedles 14 acting as electrodes. Because the dry stratum corneum of the epidermis 90 acts as a capacitive barrier while the sub-epidermal layers 92 are well conducting, the impedance of the circuit drops as the microneedles pierce through the stratum corneum 90. The change in impedance is by one or more orders of magnitude and reliably indicates when the microneedles nave pierced through the stratum corneum 90. Furthermore, at less than 1 Volt, the voltage stimulus is not felt by the subject. Note that the microneedles 14 are electrically isolated from the base. An illustrative embodiment of a circuit diagram of the circuit used here is shown in FIG. 8B, where the Z,Qad represents the unknown impedance.
As an example, impedance measurements of pig skin is illustrated in FIG.
9A. The top portion 94 of the graph illustrates the measured impedance of pig skin over a frequency range before a microneedle penetrates the stratum corneum and the bottom portion 96 represents the measured impedance after the microneedle has penetrated the stratum corneum. As can be seen, the difference between the two portions 94 and 96 of the graph can be over three orders of magnitude. Turning also to FIG. 9B, there is shown a plot of impedance versus the perpendicular depth into the skin, which clearly illustrate that the penetration into the skin produces smaller impedances.
Rather than sweeping over a frequency range, the input signal of the impedance sensor 32 can be set at one frequency. The input signal can be a square wave generated by an embedded processor such as a TI-MSP430F149IPM, produced by Texas Instruments of Dallas, Texas. Certain characteristics of this chip are that it draws 35 pA when active, and less than 1 ~A in low power mode, and has a 64 pin PQFP package, a 1.8 to 3.6 V power supply, 8 analog to digital converters, 60 kbytes of flash memory, 2 kbytes of RAM, 2 16-bit timers, and an on-chip comparator.
1 S Alternatively, a processor such as a TI-MSP430F1 lOIPW can be used. This chip draws 35 ~.A when active, and less than 1 ~.A in low power mode, and includes a 20 pin TSSOP, 1.8 to 3.6 V power supply, 1 kbyte of flash memory, 128 bytes of RAM, and a 16-bit timer. Regardless which processor is used, the output signal can be pulse width modulated, and the impedance sensor 32 can be provided with a log transformer to compress the output signal to within the range of the analog to digital converter of the processor.
As mentioned earlier, in certain embodiments, a glucose sensor is associated with the transport device 10. In these embodiments, fluid is withdrawn from the patient through the microneedles 14 into one of a multiplicity of reservoir chambers.
The glucose sensor is at least partially in one of the chambers, where it can detect the concentration of glucose in the fluid. Information from the glucose sensor is read and interpreted by the operator of the device 10, for example, with the use of the display 22 of the applicator 12, who can then activate another chamber of the reservoir to deliver the appropriate amount of insulin to bring the glucose concentration to an appropriate Ievel. Alternatively, the procedure can be automated so that the glucose sensor reads the glucose concentration in the fluid, and, based on that concentration, sends a signal, such as an electronic signal, to the other chamber, "telling" that chamber whether or not to deliver insulin through a set of microneedles, and how much insulin to deliver.
In any of the above describe embodiments, one or more controllers such as a programmable microprocessor located in the transport device 10 andlor the applicator 12 can control and coordinate the actuators, pumps, sensors, and oscillators. For example, the controller can instruct the actuator 52 to pump a specified amount of drug into a patient at a specified time. The specified amount may be the full amount contained in the reservoir 46 or a partial amount.
Thus, the device is able to inject a partial or full amount of drug incrementally over a desired time period. One controller may control the operation of the applicator 12, while another controller controls the operation of the device 10. Alternatively, a single controller may control the operations of the applicator 12 and the device 10.
In any case, the applicator 12 and/or the device 10 can communicate with each other or 1 S with a central processor, for instance, using wireless communications capabilities provided with either or both the applicator 12 and the device 10.
The transdermal transport device 10 is not limited to the embodiments described above. For example, other embodiments of the transdermal transport device 10 are shown in FIGS. 10 and 1 l, where like reference numerals identify like features.
In the device 10 of FIG. 10, the microneedles 14 are again bent at about a 90°
angle. They are oriented so that there is a section that is parallel to the surface of the skin S and a section that is perpendicular to the base 36 of the device 10.
The microneedles 14 are soldered or attached in any suitable manner to a needle plate 100 that is able to turn, but not able to translate. In this embodiment, the microneedles 41 are not inserted into the drug vial 40 until just before delivery. The pump assembly or actuator 52 is pinned in place by three pins that slide in angled slots 101 as the inner portion of the device 10 is turned. For extra guidance and stability, the actuator 52 also rides on pins 102 in slots that are cut into the actuator 52.
The device 10 is first brought to the skin S by the applicator 12 (FIG. 1).
The electromagnet 26 in the applicator 12 turns the inside portion of the device 10, which causes the actuator 52 to translate down onto the ends 64 of the microneedles 14 as the needles are turned into the skin S while suction is being applied through the ports 14 to draw the skin S into the suction ports 60. Thus, the back ends 64 of the microneedles penetrate the vial 40 as the front ends penetrate the skin.
Alternatively, the back ends 64 of the microneedles can already be in the vial 40, while the front ends are provided with caps through which the needles penetrate, or are removed before inserting the needles into the skin. The drug in the reservoir 46 is then pumped through the microneedles 14 as the actuator 52 is activated.
The depth of insertion is controlled by hard stops 104 on the base plate 36.
The skin S is sucked into the suction ports 60 by vacuum up to these hard stops 104.
Since the microneedles 14 soldered into place at a specific depth, and the hard stops can be set to a desired distance from the plane of the needles, the depth of insertion can therefore be controlled.
The actuator 52 is mounted on top of the vial 40, with the flexible membrane 48 positioned between the two. The electrodes 72 are mounted inside the actuator 52, and the leads come out directly into a circuit board 106, which is mounted just above the top of the actuator 52. On the underside of the circuit board 106 are mounted the electronic components 43, and on the top side is mounted the battery or power source 45. The applicator 12 magnetically attaches to the battery 45 to hold and rotate the device 10, while electrical connection is made between the applicator 12 and the device 10 through the copper ring 42.
The device 10 of FIG. 10 has a height of about I S mm, while the device 10 of FIG. 11 has a lower profile with a height of about 7 mm. In FIG. 11, the microneedles 14 are mounted such that they always remain in the same plane of rotation. This helps reduce the overall height of the device 10, since open space between the ends 64 of the microneedles 14 and the drug vial 40 is not necessary.
The microneedles 14 can either be permanently affixed as part of the drug vial 40, or as a separate ring. If the microneedles I4 are mounted on a separate ring, the actuator 52 is rotated onto the back end 64 of the microneedles 14 before delivery.
Then, the entire actuator/microneedle assembly is rotated into the skin S.
The depth of insertion is controlled by the space 200 between the base 36 and the component 202 that couples the microneedles 14 to the vial 40. This component 202 could either be some sort of fluidic circuit or simply a ring that holds the microneedles 14 in place for insertion into the vial 40, or the microneedles may be part of the vial 40. Vacuum suction would still be used to draw the skin into the ports 60 before insertion of the microneedles 14.
The actuator SZ is mounted as a ring around the vial 40. The top portion 204 of the actuator 52 is still above the vial 40, and the flexible membrane 48 is located between the top portion 204 and the vial 40. However, most of the actuator 52 is placed round the outside of the vial 40. This helps reduce the overall height of the device 10. The electrodes can be mounted as ring electrodes directly from the circuit board 106, which can also function as the top of the actuator 52. The battery 45 and 1 S the electronic components 43 are all mounted on the top of the circuit board 106.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
For example, the actuator or pump arrangements, such as the electrolytic actuator, can be used in other types of transdermal transport devices, as well, such as the devices described in the U.S. Application No. 10/238,844, filed September 9, 2002, by Angel and Hunter, the entire contents of which are incorporated herein by reference.
Claims (48)
1. A transdermal transport device, comprising:
a reservoir for holding a formulation of an active principle;
more than one needle configured to attach the device to the body, each needle having a bore extending along the length of the needle from a first end of the needle in a second end of the needle, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and an actuator which pumps the formulation through the bore of each needle between a target area of the body and the reservoir.
a reservoir for holding a formulation of an active principle;
more than one needle configured to attach the device to the body, each needle having a bore extending along the length of the needle from a first end of the needle in a second end of the needle, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and an actuator which pumps the formulation through the bore of each needle between a target area of the body and the reservoir.
2. The transdermal transport device of claim 1, wherein the second end moves in the plane to pierce the body surface.
3. The transdermal transport device of claim 1 or 2, wherein the actuator is adapted to pump the formulation into the biological body.
4. The transdermal transport device of claim 1, 2, or 3, wherein the actuator is reversible to draw the formulation into the vial.
5. The transdermal transport device of any one of claims 1 to 4, wherein each needle is positioned in a retracted state when the actuator is de-energized.
6. The transdermal transport device of any one of claims 1 to 5, wherein the actuator includes a vapor generator.
7. The transdermal transport device of any one of claims 1 to 6, wherein the actuator operates by an electrochemical process.
8. The transdermal transport device of any one of claims 1 to 7, wherein the actuator is a conductive polymer.
9. The transdermal transport device of any one of claims 1 to 8, further comprising an oscillator which causes the second end of each needle to vibrate along its length to reduce the force required to drive the needle into the body.
10. The transdermal transport device of claim 9, wherein the oscillator is a piezoelectric crystal which generates the vibration of the needle.
11. The transdermal transport device of any one of claims 1 to 10, further comprising a sensor to monitor the status of a patient.
12. The transdermal transport device of claim 11, wherein the status is the glucose concentration of the patient.
13. The transdermal transport device of claim 12 wherein the formulation is insulin, wherein the actuator is adapted to pump the insulin into the patient, the amount of insulin pumped being based on the glucose concentration.
14. The transdermal transport device of any one of claims 1 to 13, further comprising a base unit and a control unit, each needle being located within the base unit.
15. The transdermal transport device of claim 14, wherein the base unit and the control unit are separate connectable units.
16. The transdermal transport device of any one of claims 1 to 15, wherein the second end is slanted.
17. The transdermal transport device of claim 16, wherein the slanted side is beveled.
18. The transdermal transport device of any one of claims 1 to 17, further comprising a controller which provides operating instructions for the transdermal transport device.
19. The transdermal transport device of any one of claims 1 to 18, wherein at least one of the needles has a solid tip and openings positioned laterally about the bore.
20. The transdermal transport device of any one of claims I to 19, wherein the actuator moves the first end into the reservoir with the bore being in fluid communication with the reservoir.
21. The transdermal transport device of any one of claims 1 to 20, further comprising a rotary actuator which moves the second end of each needle in the plane.
22. The transdermal transport device of any one of claims 1 to 21, wherein each needle is bent.
23. A transdermal transport device, comprising:
a reservoir for holding a formulation of an active principle; and a needle which is adapted to transmit the formulation between the reservoir and a biological body, the needle having a bore extending along the length of the needle from a first end of the needle to a second end of the needle, the second end being substantially aligned in a plane parallel to a body surface of the biological body when the device is adapted to be placed on the body surface, and the second end having tip end that is slanted and defines an opening from which the formulation is dispensed to control the direction of diffusion of the formulation into the body.
a reservoir for holding a formulation of an active principle; and a needle which is adapted to transmit the formulation between the reservoir and a biological body, the needle having a bore extending along the length of the needle from a first end of the needle to a second end of the needle, the second end being substantially aligned in a plane parallel to a body surface of the biological body when the device is adapted to be placed on the body surface, and the second end having tip end that is slanted and defines an opening from which the formulation is dispensed to control the direction of diffusion of the formulation into the body.
24. The transdermal transport device of claim 23 further comprising one or more additional needles.
25. The transdermal transport device of claim 23 or 24, wherein the needle has an outer diameter of about 30 µm to 250 µm.
26. The transdermal transport device of claim 23, 24, or 25, wherein the needle has an inner diameter of about 10 µm to 100 µm.
27. The transdermal transport device of any one of claims 23 to 26, wherein the tip end is slanted between about 10° to 60°.
28. The transdermal transport device of any one of claims 23 to 27, wherein the needle is made of 304 stainless steel.
29. A transdermal transport device, comprising:
a reservoir for holding a formulation of an active principle; and a needle having a hollow pathway through which the formulation is transported between an end portion of the needle and the reservoir, the end portion having a plurality of openings along its length, the formulation being dispensed from and drawn through the plurality of openings.
a reservoir for holding a formulation of an active principle; and a needle having a hollow pathway through which the formulation is transported between an end portion of the needle and the reservoir, the end portion having a plurality of openings along its length, the formulation being dispensed from and drawn through the plurality of openings.
30. The transdermal transport device of claim 29 further comprising one or more additional needles.
31. The transdermal transport device of claim 29 or 30, wherein the needle has an outer diameter of about 30 µm to 250 µm.
32. The transdermal transport device of claim 29, 30, or 31, wherein the needle has an inner diameter of about 10 µm to 100 µm.
33. The transdermal transport device of any one of claims 29 to 32, wherein the needle has from one to 20 openings.
34. The transdermal transport device of claim 33, wherein the openings are spaced apart between about 100 µm to 2 mm.
35. The transdermal transport device of claim 33 or 34, wherein the openings are located along a side of the needle facing away from the top of the skin when the needle has penetrated the skin.
36. The transdermal transport device of claim 35 where the needle is made of stainless steel.
37. The transdermal transport device of claim 35, wherein the needle has a solid tip.
38. A transdermal transport device, comprising:
a reservoir for holding a formulation of an active principle;
a needle having a bore through which the formulation may be transmitted between the reservoir and a body;
an actuator adapted for pumping the formulation between the reservoir and the body; and a controller which is adapted to direct the actuator to pump a desired amount of the formulation, the desired amount being dependent on input specifics of the body.
a reservoir for holding a formulation of an active principle;
a needle having a bore through which the formulation may be transmitted between the reservoir and a body;
an actuator adapted for pumping the formulation between the reservoir and the body; and a controller which is adapted to direct the actuator to pump a desired amount of the formulation, the desired amount being dependent on input specifics of the body.
39. The transdermal transport device of claim 38, adapted to dispense the desired amount of the formulation from the reservoir over a particular time period.
40. The transdermal transport device of claim 39, wherein the time period is from 1 sec to 10 days.
41. The transdermal transport device of claim 39, adapted to dispense the desired amount of formulation incrementally over time.
42. The transdermal transport device of any one of claims 38 to 41, wherein the body is a human patient.
43. The transdermal transport device of any one of claims 38 to 42, wherein the desired amount of the formulation is a sample collected from a patient drawn into the reservoir over a particular time period.
44. A transdermal transport device, comprising:
a means for holding a formulation of an active principle;
a means for transporting the formulation between the means for holding and a target area of the body, the means for transporting having a first end and a second end, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and a means for pumping the formulation between the target area of the body and the first end of the means for holding.
a means for holding a formulation of an active principle;
a means for transporting the formulation between the means for holding and a target area of the body, the means for transporting having a first end and a second end, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and a means for pumping the formulation between the target area of the body and the first end of the means for holding.
45. The transdermal transport device of claim 22, wherein each bent needle defines a bend angle less than 180°.
46. The transdermal transport device of claim 45, wherein the bend angle is approximately 90°.
47. A transdermal transport device, comprising:
a reservoir for holding a formulation of an active principle;
a bent needle having a bore extending along the length of the bent needle from a first end of the bent needle to a second end of the bent needle, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and an actuator adapted to pump the formulation through the bore of the bent needle between a target area of the body and the reservoir.
a reservoir for holding a formulation of an active principle;
a bent needle having a bore extending along the length of the bent needle from a first end of the bent needle to a second end of the bent needle, the second end being substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface; and an actuator adapted to pump the formulation through the bore of the bent needle between a target area of the body and the reservoir.
48. Use of the transdermal transport device of any one of claims 1 to 47, for transporting a formulation of an active principle.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33842501P | 2001-10-26 | 2001-10-26 | |
US60/338,425 | 2001-10-26 | ||
US39948902P | 2002-07-29 | 2002-07-29 | |
US60/399,489 | 2002-07-29 | ||
PCT/US2002/033794 WO2003037404A1 (en) | 2001-10-26 | 2002-10-21 | Microneedle transdermal transport device |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2464485A1 CA2464485A1 (en) | 2003-05-08 |
CA2464485C true CA2464485C (en) | 2010-05-11 |
Family
ID=26991185
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2464483A Expired - Fee Related CA2464483C (en) | 2001-10-26 | 2002-10-18 | Microneedle transport device |
CA2464485A Expired - Fee Related CA2464485C (en) | 2001-10-26 | 2002-10-21 | Microneedle transdermal transport device |
CA2464670A Expired - Fee Related CA2464670C (en) | 2001-10-26 | 2002-10-22 | Transdermal transport device with suction |
CA002464487A Abandoned CA2464487A1 (en) | 2001-10-26 | 2002-10-22 | Transdermal transport device with an electrolytic actuator |
CA2464673A Expired - Fee Related CA2464673C (en) | 2001-10-26 | 2002-10-22 | Impedance sensor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2464483A Expired - Fee Related CA2464483C (en) | 2001-10-26 | 2002-10-18 | Microneedle transport device |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2464670A Expired - Fee Related CA2464670C (en) | 2001-10-26 | 2002-10-22 | Transdermal transport device with suction |
CA002464487A Abandoned CA2464487A1 (en) | 2001-10-26 | 2002-10-22 | Transdermal transport device with an electrolytic actuator |
CA2464673A Expired - Fee Related CA2464673C (en) | 2001-10-26 | 2002-10-22 | Impedance sensor |
Country Status (8)
Country | Link |
---|---|
US (7) | US7429258B2 (en) |
EP (5) | EP1439871B1 (en) |
JP (10) | JP2005525141A (en) |
AT (3) | ATE420680T1 (en) |
AU (3) | AU2002353840B2 (en) |
CA (5) | CA2464483C (en) |
DE (3) | DE60230896D1 (en) |
WO (5) | WO2003037403A1 (en) |
Families Citing this family (391)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6471635B1 (en) | 2000-02-10 | 2002-10-29 | Obtech Medical Ag | Anal incontinence disease treatment with controlled wireless energy supply |
US6464628B1 (en) | 1999-08-12 | 2002-10-15 | Obtech Medical Ag | Mechanical anal incontinence |
US6503189B1 (en) | 1999-08-12 | 2003-01-07 | Obtech Medical Ag | Controlled anal incontinence disease treatment |
US6482145B1 (en) | 2000-02-14 | 2002-11-19 | Obtech Medical Ag | Hydraulic anal incontinence treatment |
CN1202784C (en) | 2000-02-10 | 2005-05-25 | 波滕西亚医疗公司 | Controlled urinary incontinence treatment |
DE60135257D1 (en) | 2000-02-10 | 2008-09-18 | Potencia Medical Ag | Mechanical device for impotence treatment |
CA2398496C (en) | 2000-02-10 | 2009-05-19 | Surgical Development Ag | Urinary incontinence treatment with wireless energy supply |
CN1400888A (en) | 2000-02-11 | 2003-03-05 | 波滕西亚医疗公司 | Impotence treatment apparatus with energy transforming means |
AU778406B2 (en) | 2000-02-11 | 2004-12-02 | Potentica Ag | Controlled impotence treatment |
WO2001047440A2 (en) | 2000-02-14 | 2001-07-05 | Potencia Medical Ag | Male impotence prosthesis apparatus with wireless energy supply |
US20030100929A1 (en) | 2000-02-14 | 2003-05-29 | Peter Forsell | Controlled penile prosthesis |
ATE296071T1 (en) | 2000-02-14 | 2005-06-15 | Potencia Medical Ag | PENIS PROSTHESIS |
US7419481B2 (en) * | 2000-10-13 | 2008-09-02 | Alza Corporation | Apparatus and method for piercing skin with microprotrusions |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
DE60207902T2 (en) * | 2001-01-30 | 2006-06-14 | Nissan Chemical Ind Ltd | Isocyanurate compound and process for its preparation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US6966880B2 (en) * | 2001-10-16 | 2005-11-22 | Agilent Technologies, Inc. | Universal diagnostic platform |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US6908453B2 (en) * | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US7858112B2 (en) * | 2002-02-28 | 2010-12-28 | Lintec Corporation | Percutaneous absorption system and percutaneous absorption method |
US7115108B2 (en) * | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795334B2 (en) * | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8784335B2 (en) * | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US20040039289A1 (en) * | 2002-04-30 | 2004-02-26 | Christensen Lars Hofmann | Needle insertion sensor |
CA2484265C (en) | 2002-05-06 | 2012-08-07 | Becton, Dickinson And Company | Method and device for controlling drug pharmacokinetics |
EP1389476A1 (en) * | 2002-08-14 | 2004-02-18 | Precimedix S.A. | Programming device for a pump for injecting medicaments |
JP2005537054A (en) * | 2002-08-30 | 2005-12-08 | ベクトン・ディキンソン・アンド・カンパニー | Methods for controlling the pharmacokinetics of immunomodulatory compounds |
US20120296233A9 (en) * | 2002-09-05 | 2012-11-22 | Freeman Dominique M | Methods and apparatus for an analyte detecting device |
US20040106894A1 (en) | 2002-09-06 | 2004-06-03 | Massachusetts Institute Of Technology | Needleless drug injection device |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
KR20050105100A (en) * | 2003-03-06 | 2005-11-03 | 라이프스캔, 인코포레이티드 | System and method for piecing dermal tissue |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
MXPA06001414A (en) * | 2003-08-04 | 2006-08-25 | Johnson & Johnson | Method and device for enhancing transdermal agent flux. |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
EP1527792A1 (en) | 2003-10-27 | 2005-05-04 | Novo Nordisk A/S | Medical injection device mountable to the skin |
EP1680154B1 (en) * | 2003-10-31 | 2012-01-04 | ALZA Corporation | Self-actuating applicator for microprojection array |
US7361182B2 (en) | 2003-12-19 | 2008-04-22 | Lightnix, Inc. | Medical lancet |
DK1706019T3 (en) * | 2003-12-22 | 2009-02-02 | Paul Hadvary | Dermally attached sensor device |
CA2552385C (en) * | 2003-12-29 | 2013-07-23 | 3M Innovative Properties Company | Medical devices and kits including same |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
EP3466483A1 (en) | 2004-03-08 | 2019-04-10 | Ichor Medical Systems Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
WO2005110525A2 (en) * | 2004-04-12 | 2005-11-24 | Allergan, Inc. | Multi-site injection system |
WO2005118060A2 (en) * | 2004-04-30 | 2005-12-15 | Boston Scientific Limited | Apparatus with partially insulated needle for measuring tissue impedance and method using same |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US9775553B2 (en) * | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
WO2005120365A1 (en) * | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US7872396B2 (en) * | 2004-06-14 | 2011-01-18 | Massachusetts Institute Of Technology | Electrochemical actuator |
EP1784890A4 (en) | 2004-06-14 | 2010-04-07 | Massachusetts Inst Technology | Electrochemical methods, devices, and structures |
US8247946B2 (en) * | 2004-06-14 | 2012-08-21 | Massachusetts Institute Of Technology | Electrochemical actuator |
JP2008504895A (en) * | 2004-06-29 | 2008-02-21 | スパイン・ウェイブ・インコーポレーテッド | Method for treating disc defects and injuries |
US20060030811A1 (en) * | 2004-08-03 | 2006-02-09 | Wong Patrick S | Method and device for enhancing transdermal agent flux |
WO2006016364A2 (en) * | 2004-08-10 | 2006-02-16 | Hellman De Picciotto, Tania | Drug delivery devices |
WO2006018642A1 (en) | 2004-08-16 | 2006-02-23 | Functional Microstructures Limited | Method of producing a microneedle or microimplant |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
WO2006055799A1 (en) * | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
KR20070102669A (en) * | 2004-11-18 | 2007-10-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Low-profile microneedle array applicator |
JP5015787B2 (en) | 2004-11-18 | 2012-08-29 | スリーエム イノベイティブ プロパティズ カンパニー | Contact coating method of microneedle array |
ATE504328T1 (en) | 2004-11-18 | 2011-04-15 | 3M Innovative Properties Co | MICRONEEDLE ARRANGEMENT APPLICATOR AND HOLDER |
US20080009801A1 (en) * | 2004-12-02 | 2008-01-10 | Nickel Janice H | Method for dispensing material into a drug delivery device |
CN100367906C (en) * | 2004-12-08 | 2008-02-13 | 圣美迪诺医疗科技(湖州)有限公司 | Endermic implantating biological sensors |
US7833189B2 (en) * | 2005-02-11 | 2010-11-16 | Massachusetts Institute Of Technology | Controlled needle-free transport |
US7850645B2 (en) * | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
EP1709989A1 (en) * | 2005-04-04 | 2006-10-11 | Christoph Burckhardt AG | Tattoo machine |
JP5301985B2 (en) * | 2005-04-07 | 2013-09-25 | スリーエム イノベイティブ プロパティズ カンパニー | System and method for tool feedback sensing |
EP1709906A1 (en) * | 2005-04-07 | 2006-10-11 | F. Hoffmann-La Roche Ag | Method and device for blood sampling |
US8298172B2 (en) | 2005-04-13 | 2012-10-30 | Novo Nordisk A/S | Medical skin mountable device and system |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
EP2921169A1 (en) * | 2005-05-24 | 2015-09-23 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US20080269666A1 (en) * | 2005-05-25 | 2008-10-30 | Georgia Tech Research Corporation | Microneedles and Methods for Microinfusion |
EP1884259A4 (en) * | 2005-05-27 | 2011-03-30 | Olympus Corp | Device for introduction into subject |
US8505544B2 (en) * | 2005-05-31 | 2013-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-implemented microsurgery system and approach |
WO2006134153A1 (en) | 2005-06-16 | 2006-12-21 | Novo Nordisk A/S | Method and apparatus for assisting patients in self administration of medication |
EP1904158B1 (en) | 2005-06-24 | 2013-07-24 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
CA2613111C (en) * | 2005-06-27 | 2015-05-26 | 3M Innovative Properties Company | Microneedle array applicator device and method of array application |
JP5006317B2 (en) | 2005-07-06 | 2012-08-22 | バスキュラー・パスウェイズ・インコーポレイテッド | Intravenous catheter insertion device and method of using the same |
US9687186B2 (en) | 2005-07-21 | 2017-06-27 | Steadymed Ltd. | Drug delivery device |
IL175460A (en) | 2006-05-07 | 2011-05-31 | Doron Aurbach | Drug delivery device |
US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9358033B2 (en) | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
US10548659B2 (en) | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US20070185432A1 (en) * | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
US20070066934A1 (en) * | 2005-09-19 | 2007-03-22 | Transport Pharmaceuticals, Inc. | Electrokinetic delivery system and methods therefor |
US8113244B2 (en) * | 2006-02-09 | 2012-02-14 | Deka Products Limited Partnership | Adhesive and peripheral systems and methods for medical devices |
JP4935286B2 (en) * | 2005-10-12 | 2012-05-23 | パナソニック株式会社 | Blood sensor |
CN101291697B (en) | 2005-10-17 | 2011-05-18 | 诺沃-诺迪斯克有限公司 | Vented drug reservoir unit |
EP2926847B1 (en) * | 2005-11-02 | 2022-05-25 | MedicalTree Patents Ltd. | Implantable infusion device with advanceable and retractable needle |
US7885793B2 (en) | 2007-05-22 | 2011-02-08 | International Business Machines Corporation | Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution |
US9248317B2 (en) | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US9636035B2 (en) * | 2005-12-14 | 2017-05-02 | Scibase Ab | Medical apparatus for determination of biological conditions using impedance measurements |
JP4402648B2 (en) * | 2005-12-16 | 2010-01-20 | オリンパス株式会社 | Intra-subject introduction device |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
EP1815790A1 (en) * | 2006-02-04 | 2007-08-08 | Roche Diagnostics GmbH | Lancet device with impedance measuring unit |
US11318249B2 (en) | 2006-02-09 | 2022-05-03 | Deka Products Limited Partnership | Infusion pump assembly |
ATE532553T1 (en) * | 2006-02-10 | 2011-11-15 | Hisamitsu Pharmaceutical Co | TRANSDERMAL DRUG ADMINISTRATION DEVICE WITH MICRONEEDLES |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
WO2007106557A2 (en) | 2006-03-14 | 2007-09-20 | University Of Southern California | Mems device for delivery of therapeutic agents |
US9119945B2 (en) * | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
WO2007131050A2 (en) * | 2006-05-02 | 2007-11-15 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US7621895B2 (en) * | 2006-05-17 | 2009-11-24 | Abbott Cardiovascular Systems Inc. | Needle array devices and methods |
US20070276318A1 (en) * | 2006-05-26 | 2007-11-29 | Mit, Llp | Iontosonic-microneedle applicator apparatus and methods |
US20090171269A1 (en) * | 2006-06-29 | 2009-07-02 | Abbott Diabetes Care, Inc. | Infusion Device and Methods Therefor |
US9119582B2 (en) * | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
JP2009545368A (en) * | 2006-08-01 | 2009-12-24 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Ultrasonic enhanced micro needle |
US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
WO2008027011A1 (en) * | 2006-08-28 | 2008-03-06 | Agency For Science, Technology And Research | Microneedles and methods for fabricating microneedles |
WO2008027218A2 (en) * | 2006-08-29 | 2008-03-06 | Alza Corporation | Drug electrotransport with hydration measurement of hydratable reservoir |
EP2063934A1 (en) * | 2006-09-18 | 2009-06-03 | Agency for Science, Technology and Research | Needle structures and methods for fabricating needle structures |
AU2007303821B9 (en) * | 2006-10-05 | 2013-06-20 | Technion Research & Development Foundation Ltd. | Microtubes and methods of producing same |
DK2084802T3 (en) * | 2006-10-25 | 2019-05-13 | Hoffmann La Roche | Uninterruptible power supply for medical device |
US20080117416A1 (en) * | 2006-10-27 | 2008-05-22 | Hunter Ian W | Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same |
US10525246B2 (en) * | 2006-12-22 | 2020-01-07 | Nanomed Skincare, Inc. | Microdevice and method for transdermal delivery and sampling of active substances |
US8845530B2 (en) * | 2007-01-02 | 2014-09-30 | Isense Corporation | Resposable biosensor assembly and method of sensing |
FR2912919B1 (en) * | 2007-02-22 | 2009-05-01 | Bernard Perriere | MINIATURIZED INJECTION DEVICE FOR MEDICAL USE |
US20080249469A1 (en) * | 2007-03-22 | 2008-10-09 | Ponnambalam Selvaganapathy | Method and apparatus for active control of drug delivery using electro-osmotic flow control |
GB2448493B (en) * | 2007-04-16 | 2009-10-14 | Dewan Fazlul Hoque Chowdhury | Microneedle transdermal delivery device |
US9114238B2 (en) | 2007-04-16 | 2015-08-25 | Corium International, Inc. | Solvent-cast microprotrusion arrays containing active ingredient |
US8721546B2 (en) | 2007-05-07 | 2014-05-13 | Vascular Pathways, Inc. | Intravenous catheter insertion and blood sample devices and method of use |
WO2008154338A1 (en) * | 2007-06-07 | 2008-12-18 | Piezo Resonance Innovations, Inc. | Eye surgical tool |
CN101677988A (en) * | 2007-06-21 | 2010-03-24 | 藤本株式会社 | Composition for transdermal or transmucosal administration |
US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
US8085151B2 (en) | 2007-06-28 | 2011-12-27 | Abbott Diabetes Care Inc. | Signal converting cradle for medical condition monitoring and management system |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9987468B2 (en) | 2007-06-29 | 2018-06-05 | Actuated Medical, Inc. | Reduced force device for intravascular access and guidewire placement |
US8043229B2 (en) * | 2007-06-29 | 2011-10-25 | Actuated Medical, Inc. | Medical tool for reduced penetration force |
US8328738B2 (en) | 2007-06-29 | 2012-12-11 | Actuated Medical, Inc. | Medical tool for reduced penetration force with feedback means |
US10219832B2 (en) | 2007-06-29 | 2019-03-05 | Actuated Medical, Inc. | Device and method for less forceful tissue puncture |
US7828771B2 (en) * | 2007-07-26 | 2010-11-09 | Entra Pharmaceuticals, Inc. | Systems and methods for delivering drugs |
CA2941187C (en) * | 2007-08-14 | 2021-03-02 | Fred Hutchinson Cancer Research Center | Needle array assembly and method for delivering therapeutic agents |
WO2009029572A1 (en) * | 2007-08-24 | 2009-03-05 | Deka Products Limited Partnership | Microneedle systems and apparatus |
WO2009029044A1 (en) * | 2007-08-24 | 2009-03-05 | Agency For Science, Technology And Research | A system and method for detecting skin penetration |
US9096845B2 (en) * | 2007-08-29 | 2015-08-04 | Technion Research & Development Foundation Limited | Encapsulation of bacteria and viruses in electrospun fibers |
US20090088682A1 (en) * | 2007-09-28 | 2009-04-02 | Seattle Medical Technologies | Wearable infusion device |
US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
JP5461427B2 (en) * | 2007-12-17 | 2014-04-02 | ニューワールド ファーマシューティカルズ,エルエルシー | Integrated intradermal delivery, diagnosis and communication system |
EP2242464B2 (en) | 2007-12-20 | 2017-03-01 | University Of Southern California | Apparatus for delivering therapeutic agents |
FI20075978A0 (en) * | 2007-12-31 | 2007-12-31 | Katja Paassilta | Arrangement and method |
BR122019016154B8 (en) | 2007-12-31 | 2021-06-22 | Deka Products Lp | infusion pump set |
US11357910B2 (en) | 2007-12-31 | 2022-06-14 | Deka Products Limited Partnership | Pump assembly with switch |
WO2009088956A2 (en) | 2007-12-31 | 2009-07-16 | Deka Products Limited Partnership | Infusion pump assembly |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
EP3964243A1 (en) | 2008-01-28 | 2022-03-09 | Implantica Patent Ltd | Blood clot removal device, system, and method |
BRPI0906746A8 (en) | 2008-01-29 | 2019-05-14 | Implantica Patent Ltd | apparatus for treating gastresophageal reflux disease |
US9297094B2 (en) * | 2008-02-21 | 2016-03-29 | Technion Research & Development Foundation Ltd. | Use of electrospun microtubes for drug delivery |
US20090221893A1 (en) * | 2008-02-29 | 2009-09-03 | Path Scientific, Llc | Unitized Painfree Blood Glucose Measuring Device |
JP2009222474A (en) * | 2008-03-14 | 2009-10-01 | Panasonic Corp | Micro-liquid transfer apparatus and micro-mliquid transfer method |
CN102202708B (en) | 2008-05-08 | 2015-01-21 | 迷你泵有限责任公司 | Drug-delivery pumps and methods of manufacture |
US9849238B2 (en) | 2008-05-08 | 2017-12-26 | Minipumps, Llc | Drug-delivery pump with intelligent control |
CA2723724C (en) | 2008-05-08 | 2017-03-14 | Replenish Pumps, Llc | Implantable pumps and cannulas therefor |
JP5584202B2 (en) | 2008-05-21 | 2014-09-03 | セラジェクト, インコーポレイテッド | Method for manufacturing solid solution punch patch and use thereof |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
JP2011526889A (en) | 2008-06-30 | 2011-10-20 | アフギン ファーマ,エルエルシー | Local nerve action therapy |
JP4482617B2 (en) * | 2008-07-08 | 2010-06-16 | パナソニック株式会社 | Fluid transfer device using conductive polymer |
US8868176B2 (en) * | 2008-07-22 | 2014-10-21 | New York University | Microelectrode-equipped subdural therapeutic agent delivery strip |
DK2626093T3 (en) * | 2008-08-28 | 2014-02-24 | Hoffmann La Roche | DEVICE FOR INCREASING HYPODERMIC insulin absorption |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
US11123171B2 (en) | 2008-10-10 | 2021-09-21 | Peter Forsell | Fastening means for implantable medical control assembly |
ES2950024T3 (en) | 2008-10-10 | 2023-10-04 | Medicaltree Patent Ltd | Heart support device, system and procedure |
US9072907B2 (en) | 2008-10-10 | 2015-07-07 | Peter Forsell | Heart help device, system, and method |
EP2349170B1 (en) | 2008-10-10 | 2023-09-27 | Implantica Patent Ltd. | Apparatus for the treatment of female sexual dysfunction |
US8874215B2 (en) | 2008-10-10 | 2014-10-28 | Peter Forsell | System, an apparatus, and a method for treating a sexual dysfunctional female patient |
EP2349096B1 (en) | 2008-10-10 | 2021-01-27 | MedicalTree Patent Ltd. | An improved artificial valve |
WO2010052692A1 (en) * | 2008-11-04 | 2010-05-14 | Janisys Limited | A transfer device for transferring a substance between the device and a subject |
US20110301628A1 (en) * | 2008-12-05 | 2011-12-08 | Yossi Gross | Techniques for use with a nail penetration device |
US9358375B2 (en) | 2008-12-19 | 2016-06-07 | Janisys Limited | Fluid transfer device and an active substance cartridge for the fluid transfer device, and a method for controlling the pressure at which an active substance is delivered to a subject from a fluid transfer device |
US20100187132A1 (en) * | 2008-12-29 | 2010-07-29 | Don Alden | Determination of the real electrochemical surface areas of screen printed electrodes |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US20110172510A1 (en) * | 2010-01-13 | 2011-07-14 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or withdrawal of fluids |
US20110105951A1 (en) * | 2009-10-30 | 2011-05-05 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
US8827971B2 (en) | 2011-04-29 | 2014-09-09 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
WO2010101620A2 (en) * | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin |
JP5563652B2 (en) * | 2009-03-17 | 2014-07-30 | カーディオスライヴ インコーポレイテッド | External defibrillator |
US8781576B2 (en) * | 2009-03-17 | 2014-07-15 | Cardiothrive, Inc. | Device and method for reducing patient transthoracic impedance for the purpose of delivering a therapeutic current |
DE102009002019A1 (en) | 2009-03-31 | 2010-10-07 | Robert Bosch Gmbh | Applicator for the treatment of skin |
EP2424610A2 (en) * | 2009-04-29 | 2012-03-07 | Janisys Limited | A micro-needle device and apparatus and a method for applying a micro-needle element to a site on the skin of a subject |
WO2010127051A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Diabetes Care Inc. | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US20120197195A1 (en) * | 2009-05-20 | 2012-08-02 | Sanofi-Aventis Deutschland Gmbh | Drug Delivery Device |
US10952836B2 (en) | 2009-07-17 | 2021-03-23 | Peter Forsell | Vaginal operation method for the treatment of urinary incontinence in women |
US9949812B2 (en) | 2009-07-17 | 2018-04-24 | Peter Forsell | Vaginal operation method for the treatment of anal incontinence in women |
CA2769030C (en) | 2009-07-30 | 2016-05-10 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
AU2010276511B2 (en) | 2009-07-31 | 2013-09-19 | Kindeva Drug Delivery L.P. | Hollow microneedle arrays |
US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
KR101697388B1 (en) | 2009-08-18 | 2017-01-17 | 미니펌프스, 엘엘씨 | Electrolytic drug-delivery pump with adaptive control |
US8758271B2 (en) | 2009-09-01 | 2014-06-24 | Massachusetts Institute Of Technology | Nonlinear system identification techniques and devices for discovering dynamic and static tissue properties |
US20110060202A1 (en) * | 2009-09-08 | 2011-03-10 | Seth Adrian Miller | Dehydration detector using micro-needles |
JP5701882B2 (en) * | 2009-09-10 | 2015-04-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drug container |
US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
US20110143310A1 (en) * | 2009-12-15 | 2011-06-16 | Hunter Ian W | Lorentz-Force Actuated Cleaning Device |
US20110172637A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including tissue support structure |
CN102791197B (en) * | 2010-01-13 | 2016-03-23 | 第七感生物系统有限公司 | Sampler interface |
EP3243435A1 (en) * | 2010-01-13 | 2017-11-15 | Seventh Sense Biosystems, Inc. | Sampling device interfaces |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
US8366667B2 (en) * | 2010-02-11 | 2013-02-05 | Baxter International Inc. | Flow pulsatility dampening devices |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP2560703A2 (en) | 2010-04-20 | 2013-02-27 | MiniPumps, LLC | Electrolytically driven drug pump devices |
MX2012012567A (en) | 2010-04-28 | 2012-11-21 | Kimberly Clark Co | Method for increasing permeability of an epithelial barrier. |
US9629979B2 (en) * | 2010-04-28 | 2017-04-25 | Sanovas, Inc. | Pressure/Vacuum actuated catheter drug delivery probe |
DK2563450T3 (en) | 2010-04-28 | 2017-11-13 | Kimberly Clark Co | Apparatus for administering rheumatoid arthritis drug |
US9526883B2 (en) | 2010-04-28 | 2016-12-27 | Kimberly-Clark Worldwide, Inc. | Composite microneedle array including nanostructures thereon |
EP2563451B1 (en) | 2010-04-28 | 2017-11-01 | Kimberly-Clark Worldwide, Inc. | MEDICAL DEVICES FOR DELIVERY OF siRNA |
AU2011248108B2 (en) | 2010-05-04 | 2016-05-26 | Corium Pharma Solutions, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
US8337457B2 (en) | 2010-05-05 | 2012-12-25 | Springleaf Therapeutics, Inc. | Systems and methods for delivering a therapeutic agent |
US9872971B2 (en) | 2010-05-14 | 2018-01-23 | C. R. Bard, Inc. | Guidewire extension system for a catheter placement device |
US10384039B2 (en) | 2010-05-14 | 2019-08-20 | C. R. Bard, Inc. | Catheter insertion device including top-mounted advancement components |
US9950139B2 (en) | 2010-05-14 | 2018-04-24 | C. R. Bard, Inc. | Catheter placement device including guidewire and catheter control elements |
US8932258B2 (en) | 2010-05-14 | 2015-01-13 | C. R. Bard, Inc. | Catheter placement device and method |
US11925779B2 (en) | 2010-05-14 | 2024-03-12 | C. R. Bard, Inc. | Catheter insertion device including top-mounted advancement components |
WO2011156095A2 (en) | 2010-06-10 | 2011-12-15 | The Regents Of The University Of California | Textile-based printable electrodes for electrochemical sensing |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US9227021B2 (en) | 2010-06-29 | 2016-01-05 | Genesis Biosystems, Inc. | Microneedle roller (MNR) infusion system |
JP2013538069A (en) | 2010-07-16 | 2013-10-10 | セブンス センス バイオシステムズ,インコーポレーテッド | Low pressure environment for fluid transfer devices |
US8814792B2 (en) | 2010-07-27 | 2014-08-26 | Carefusion 303, Inc. | System and method for storing and forwarding data from a vital-signs monitor |
US9017255B2 (en) | 2010-07-27 | 2015-04-28 | Carefusion 303, Inc. | System and method for saving battery power in a patient monitoring system |
US9615792B2 (en) | 2010-07-27 | 2017-04-11 | Carefusion 303, Inc. | System and method for conserving battery power in a patient monitoring system |
US9055925B2 (en) | 2010-07-27 | 2015-06-16 | Carefusion 303, Inc. | System and method for reducing false alarms associated with vital-signs monitoring |
US9357929B2 (en) | 2010-07-27 | 2016-06-07 | Carefusion 303, Inc. | System and method for monitoring body temperature of a person |
US9420952B2 (en) | 2010-07-27 | 2016-08-23 | Carefusion 303, Inc. | Temperature probe suitable for axillary reading |
US9585620B2 (en) | 2010-07-27 | 2017-03-07 | Carefusion 303, Inc. | Vital-signs patch having a flexible attachment to electrodes |
DE102010038733A1 (en) | 2010-07-30 | 2012-02-02 | Robert Bosch Gmbh | Modular microneedle transport device |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US9173994B2 (en) * | 2010-08-20 | 2015-11-03 | Purdue Research Foundation | Touch-actuated micropump for transdermal drug delivery and method of use |
CA2812877C (en) | 2010-09-27 | 2019-02-12 | Steadymed, Ltd. | Size-efficient drug-delivery device |
CN107096101A (en) | 2010-10-07 | 2017-08-29 | 麻省理工学院 | Use the injecting method of servo-controlled needleless injector |
US8821434B2 (en) | 2010-10-07 | 2014-09-02 | Massachusetts Institute Of Technology | Delivery of a solid body and/or a fluid using a linear Lorentz-force actuated needle-free jet injection system |
CN106214321B (en) | 2010-10-15 | 2018-08-28 | 科尼尔赛德生物医学公司 | Device for entering eyes |
WO2012058192A1 (en) * | 2010-10-26 | 2012-05-03 | 7944942 Canada Inc. | Automatic medication injection device |
US9017289B2 (en) | 2010-11-03 | 2015-04-28 | Covidien Lp | Transdermal fluid delivery device |
US8808202B2 (en) | 2010-11-09 | 2014-08-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
CA2821979A1 (en) | 2010-12-17 | 2012-06-21 | Yet-Ming Chiang | Electrochemical actuators |
US8690833B2 (en) | 2011-01-31 | 2014-04-08 | Vascular Pathways, Inc. | Intravenous catheter and insertion device with reduced blood spatter |
US10130761B2 (en) | 2011-02-09 | 2018-11-20 | Becton, Dickinson And Company | Infusion systems |
EP3563898B1 (en) | 2011-02-25 | 2020-11-11 | C.R. Bard, Inc. | Medical component insertion device including a retractable needle |
US8696637B2 (en) | 2011-02-28 | 2014-04-15 | Kimberly-Clark Worldwide | Transdermal patch containing microneedles |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012139593A2 (en) * | 2011-04-15 | 2012-10-18 | Rigshospitalet Copenhagen University Hospital | System and method for injecting a substance into a human body |
AU2012245372A1 (en) * | 2011-04-19 | 2013-11-14 | Invisiderm, Llc | Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof |
BR112013027010A2 (en) * | 2011-04-19 | 2016-12-27 | Invisiderm Llc | method of producing substances with supersaturated gas, device for their transdermal delivery, and their uses |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
CA2833175A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Devices and methods for collection and/or manipulation of blood spots or other bodily fluids |
USD903101S1 (en) | 2011-05-13 | 2020-11-24 | C. R. Bard, Inc. | Catheter |
US8636696B2 (en) * | 2011-06-10 | 2014-01-28 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
KR101542549B1 (en) | 2011-09-02 | 2015-08-06 | 산디아 코포레이션 | Microneedle arrays for biosensing and drug delivery |
DK3542851T3 (en) | 2011-10-27 | 2022-03-14 | Sorrento Therapeutics Inc | IMPLANTABLE DEVICES FOR DELIVERING BIOACTIVE MEANS |
JP6100271B2 (en) | 2011-10-27 | 2017-03-22 | キンバリー クラーク ワールドワイド インコーポレイテッド | Transdermal delivery of highly viscous bioactive agents |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
CN104023760A (en) | 2011-10-28 | 2014-09-03 | 普莱萨格生命科学公司 | Methods for drug delivery |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
DE102011089723A1 (en) * | 2011-12-23 | 2013-06-27 | Robert Bosch Gmbh | Microneedle array applicator and method of applying a microneedle array |
US10130800B2 (en) | 2012-01-27 | 2018-11-20 | Invisiderm, Llc | Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof |
WO2013136176A1 (en) * | 2012-03-13 | 2013-09-19 | Becton Dickinson France | Injection device having a miniaturized drug delivery portion |
ES2672239T3 (en) | 2012-03-15 | 2018-06-13 | Steadymed Ltd. | Improved pain reduction at the infusion site for drug delivery devices |
US9724462B2 (en) | 2012-03-19 | 2017-08-08 | Steadymed Ltd. | Fluid-connection mechanism for patch-pumps |
KR20130114996A (en) * | 2012-04-10 | 2013-10-21 | 삼성디스플레이 주식회사 | Display apparatus and fabricating method thereof |
CA3077452C (en) | 2012-05-01 | 2022-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Tip-loaded microneedle arrays for transdermal insertion |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
EP2872222B1 (en) * | 2012-07-06 | 2023-05-31 | The General Hospital Corporation | Method and apparatus for dermatological treatment |
US9782538B2 (en) | 2012-09-27 | 2017-10-10 | Becton, Dickinson And Company | Angled inserter for drug infusion |
MX2015005839A (en) | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects. |
SI2922554T1 (en) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminally modified rna |
MX2015008157A (en) | 2012-12-21 | 2016-02-22 | Corium Int Inc | Microarray for delivery of therapeutic agent and methods of use. |
EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
CN105102054B (en) | 2013-01-30 | 2018-04-20 | 血管通路股份有限公司 | The system and method placed for venipuncture and conduit |
BR112015020328B1 (en) * | 2013-02-28 | 2022-05-31 | Sorrento Therapeutics, Inc | Transdermal drug delivery device |
EP4094799A1 (en) | 2013-03-12 | 2022-11-30 | Corium, Inc. | Microprojection applicators |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
JP6098250B2 (en) * | 2013-03-14 | 2017-03-22 | セイコーエプソン株式会社 | Liquid transport device |
US10080839B2 (en) | 2013-03-14 | 2018-09-25 | Becton, Dickinson And Company | Angled inserter for drug infusion |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
JP2016514133A (en) | 2013-03-15 | 2016-05-19 | コリウム インターナショナル, インコーポレイテッド | MICROARRAY CONTAINING FINE STRUCTURE CONTAINING NO POLYMER, MANUFACTURING METHOD AND USE METHOD |
WO2014143770A1 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Body contour adaptable autoinjector device |
RU2711567C2 (en) | 2013-03-15 | 2020-01-17 | Кориум, ИНК. | Microchip for drug delivery and methods for use thereof |
US9821113B2 (en) | 2013-03-15 | 2017-11-21 | Becton, Dickinson And Company | Automatic angled infusion set assembly |
US9603995B2 (en) | 2013-03-15 | 2017-03-28 | Tandem Diabetes Care. Inc. | Device and method for setting therapeutic parameters for an infusion device |
US10195409B2 (en) * | 2013-03-15 | 2019-02-05 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
CN105246529B (en) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | Device and method for ocular injection |
US20140350518A1 (en) | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Syringe extrusion accessory |
US20140350516A1 (en) | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Mechanical syringe accessory |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
US9616243B2 (en) | 2013-06-14 | 2017-04-11 | Cardiothrive, Inc. | Dynamically adjustable multiphasic defibrillator pulse system and method |
US9656094B2 (en) | 2013-06-14 | 2017-05-23 | Cardiothrive, Inc. | Biphasic or multiphasic pulse generator and method |
US10149973B2 (en) | 2013-06-14 | 2018-12-11 | Cardiothrive, Inc. | Multipart non-uniform patient contact interface and method of use |
US10279189B2 (en) | 2013-06-14 | 2019-05-07 | Cardiothrive, Inc. | Wearable multiphasic cardioverter defibrillator system and method |
US9833630B2 (en) | 2013-06-14 | 2017-12-05 | Cardiothrive, Inc. | Biphasic or multiphasic pulse waveform and method |
US9907970B2 (en) | 2013-06-14 | 2018-03-06 | Cardiothrive, Inc. | Therapeutic system and method using biphasic or multiphasic pulse waveform |
KR101751653B1 (en) | 2013-06-18 | 2017-06-27 | 히사미쓰 세이야꾸 가부시키가이샤 | Applicator |
ES2753423T3 (en) | 2013-06-19 | 2020-04-08 | Hisamitsu Pharmaceutical Co | Applicator |
US20150027241A1 (en) * | 2013-07-23 | 2015-01-29 | Diba Industries, Inc. | Piercing probes with offset conical piercing tip and fluid-sampling systems comprising the piercing probes |
US10299793B2 (en) | 2013-10-23 | 2019-05-28 | Valtech Cardio, Ltd. | Anchor magazine |
US20160367638A1 (en) | 2013-12-19 | 2016-12-22 | Crystal BYERS | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
GB201403773D0 (en) * | 2014-03-04 | 2014-04-16 | Univ Cardiff | Microneedle based cell delivery |
US10279106B1 (en) | 2014-05-08 | 2019-05-07 | Tandem Diabetes Care, Inc. | Insulin patch pump |
US10029048B2 (en) | 2014-05-13 | 2018-07-24 | Allergan, Inc. | High force injection devices |
JP6822843B2 (en) | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | Systems and methods for remotely processing data collected by drug delivery devices |
WO2015196085A2 (en) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
US10321858B2 (en) | 2014-08-18 | 2019-06-18 | Proteadx, Inc. | Apparatus and methods for transdermal sensing of analytes in interstitial fluid and associated data transmission systems |
US10624843B2 (en) | 2014-09-04 | 2020-04-21 | Corium, Inc. | Microstructure array, methods of making, and methods of use |
US10232146B2 (en) | 2014-09-05 | 2019-03-19 | C. R. Bard, Inc. | Catheter insertion device including retractable needle |
JP2017527394A (en) * | 2014-09-15 | 2017-09-21 | サノフイ | Drug delivery device having a rotatable housing on a base |
DE102014219719B4 (en) * | 2014-09-29 | 2018-05-03 | Ipr Intelligente Peripherien Für Roboter Gmbh | needle grippers |
US10226585B2 (en) | 2014-10-01 | 2019-03-12 | Allergan, Inc. | Devices for injection and dosing |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
JP6214786B2 (en) * | 2014-10-27 | 2017-10-18 | 深▲せん▼市光聚通訊技術開発有限公司Shenzhen Waveguider Optical Telecom Technology Inc. | Continuous blood glucose collection device and main body |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (en) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | Drug delivery device with proximity sensor |
AU2015371287A1 (en) | 2014-12-23 | 2017-06-08 | Axell Wireless Ltd. | Harmonizing noise aggregation and noise management in distributed antenna system |
EP3045185A1 (en) * | 2015-01-16 | 2016-07-20 | Sanofi-Aventis Deutschland GmbH | Connector for a container filled with a liquid medicament |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
EP3258988B1 (en) * | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US10433928B2 (en) | 2015-03-10 | 2019-10-08 | Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company | Multiple needle injector |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
USD903100S1 (en) | 2015-05-01 | 2020-11-24 | C. R. Bard, Inc. | Catheter placement device |
JP6784352B2 (en) * | 2015-05-11 | 2020-11-11 | 国立大学法人 東京医科歯科大学 | Insulin delivery device |
CA2985202C (en) | 2015-05-15 | 2023-10-10 | C.R. Bard, Inc. | Catheter placement device including an extensible needle safety component |
US10463847B2 (en) | 2015-06-11 | 2019-11-05 | Steadymed Ltd. | Infusion set |
WO2017004067A1 (en) | 2015-06-29 | 2017-01-05 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
US10940292B2 (en) | 2015-07-08 | 2021-03-09 | Actuated Medical, Inc. | Reduced force device for intravascular access and guidewire placement |
US11793543B2 (en) | 2015-09-18 | 2023-10-24 | Obvius Robotics, Inc. | Device and method for automated insertion of penetrating member |
WO2017066768A1 (en) | 2015-10-16 | 2017-04-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices |
US11744889B2 (en) | 2016-01-05 | 2023-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
EP3413851B1 (en) | 2016-02-10 | 2023-09-27 | Clearside Biomedical, Inc. | Packaging |
WO2017143153A1 (en) * | 2016-02-19 | 2017-08-24 | North Carolina State University | Methods and compositions related to physiologically responsive microneedle delivery systems |
AU2017241925B2 (en) | 2016-03-28 | 2022-01-13 | Ichor Medical Systems, Inc. | Method and apparatus for delivery of therapeutic agents |
KR102288170B1 (en) | 2016-04-08 | 2021-08-09 | 알레간 인코포레이티드 | Aspiration and injection device |
JP2019514581A (en) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | Systems and methods for ocular drug delivery |
NL2016807B1 (en) * | 2016-05-20 | 2017-11-27 | Uprax | System and method for applying microneedles |
WO2017198872A1 (en) * | 2016-05-20 | 2017-11-23 | Uprax | System and method for applying microneedles |
US10220195B2 (en) * | 2016-06-08 | 2019-03-05 | Eclipse Medcorp, Llc | Radio frequency needling device for use with disposable needle cartridges |
US10973681B2 (en) | 2016-08-12 | 2021-04-13 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
SG11201901968TA (en) | 2016-09-12 | 2019-04-29 | Bard Inc C R | Blood control for a catheter insertion device |
US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
EP3338832A1 (en) * | 2016-12-23 | 2018-06-27 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device |
JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Device and method for transdermal drug delivery |
US11400260B2 (en) | 2017-03-01 | 2022-08-02 | C. R. Bard, Inc. | Catheter insertion device |
USD867582S1 (en) | 2017-03-24 | 2019-11-19 | Allergan, Inc. | Syringe device |
CN109833562B (en) * | 2017-11-27 | 2024-03-15 | 苏州纳通生物纳米技术有限公司 | Disposable self-destruction type vibrating head assembly and permeation promoting instrument using same |
US10828500B2 (en) | 2017-12-22 | 2020-11-10 | Cardiothrive, Inc. | External defibrillator |
IL275855B2 (en) * | 2018-01-07 | 2023-11-01 | Avraham Amir | High-load microneedles and compositions for skin augmentation |
US11389626B2 (en) | 2018-03-07 | 2022-07-19 | Bard Access Systems, Inc. | Guidewire advancement and blood flashback systems for a medical device insertion system |
US11090506B2 (en) * | 2018-05-15 | 2021-08-17 | Omm Imports, Inc. | Disposable product cap and assembly having a manually usable thermo-optical device for skin care |
CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US11464955B2 (en) * | 2018-06-29 | 2022-10-11 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
USD921884S1 (en) | 2018-07-27 | 2021-06-08 | Bard Access Systems, Inc. | Catheter insertion device |
FR3084578B1 (en) * | 2018-08-03 | 2024-01-12 | Pkvitality | MANAGEMENT OF MICRONEEDLE INVESTMENT |
US11446434B2 (en) | 2019-02-22 | 2022-09-20 | Deka Products Limited Partnership | Infusion set and inserter assembly systems and methods |
WO2020188484A1 (en) * | 2019-03-19 | 2020-09-24 | King Abdullah University Of Science And Technology | Miniaturized delivery system and method |
US11590332B2 (en) * | 2019-04-17 | 2023-02-28 | Path Scientific, Llc | Precision microneedling device and methods of use |
GB201908043D0 (en) * | 2019-06-05 | 2019-07-17 | Lekkos Vasileios | Transdermal patch for therapeutic uses |
KR102279603B1 (en) * | 2019-06-11 | 2021-07-20 | (주)비올 | Needle assembly, skin stimulator including the same, and manufacturing method thereof |
EP3997452A4 (en) | 2019-07-12 | 2023-08-16 | Qulab Medical Ltd. | Electrochemical fet sensor |
WO2021020730A2 (en) * | 2019-07-26 | 2021-02-04 | 주식회사 림사이언스 | Apparatus for applying pressure to medical needle |
CN112386778A (en) | 2019-08-19 | 2021-02-23 | 贝克顿·迪金森公司 | Midline catheter placement device |
US20220379022A1 (en) * | 2019-10-30 | 2022-12-01 | Thermalin, Inc. | Agent delivery systems, devices, and methods |
CN115087480A (en) * | 2020-02-20 | 2022-09-20 | 朱比利生物科技有限公司 | Applicator for drug delivery and microneedle patch therefor |
WO2022026764A1 (en) | 2020-07-29 | 2022-02-03 | Biolinq Inc. | Continuous analyte monitoring system with microneedle array |
CN112370653B (en) * | 2020-11-12 | 2022-08-30 | 深圳市圣通生物科技有限公司 | Spray disinfection type nanometer microneedle mesoderm leading-in beauty instrument |
US20220273352A1 (en) * | 2021-03-01 | 2022-09-01 | Bluexthermal, Inc. | Device and method for thermal modulation of tissue |
US11452474B1 (en) | 2021-04-14 | 2022-09-27 | Satio, Inc. | Dual lever dermal patch system |
SE545874C2 (en) | 2021-05-08 | 2024-02-27 | Biolinq Incorporated | Fault detection for microneedle array based continuous analyte monitoring device |
US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US11510602B1 (en) | 2021-11-08 | 2022-11-29 | Satio, Inc. | Dermal patch for collecting a physiological sample |
EP4295873A1 (en) * | 2022-06-21 | 2023-12-27 | National University of Ireland Galway | An infusion catheter system |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US447225A (en) * | 1891-02-24 | Machine for attaching stays to the corners of boxes | ||
US3537A (en) | 1844-04-13 | X g gupping instrument | ||
US3659A (en) * | 1844-07-11 | Machine for hulling and pearling rice | ||
US1934043A (en) | 1929-05-17 | 1933-11-07 | Standard Oil Dev Co | Process of improvement of lubricating oils |
DE596981C (en) | 1931-10-30 | 1934-05-12 | Mario Demarchi Dr | Injection syringe |
FR757501A (en) | 1932-09-23 | 1933-12-28 | Automatic device for handling injection syringes | |
US2088780A (en) | 1936-10-09 | 1937-08-03 | Sigurd E Follese | Massage device |
US2763935A (en) | 1954-06-11 | 1956-09-25 | Purdne Res Foundation | Determining depth of layers of fat and of muscle on an animal body |
US2945496A (en) | 1958-08-18 | 1960-07-19 | Fosdal Alfred | Dental instrument for immobilizing tissue |
DE1115722B (en) | 1960-04-30 | 1961-10-26 | Hoechst Ag | Metal anode for the electrolytic separation of chlorine |
GB1128329A (en) | 1964-12-23 | 1968-09-25 | Nat Res Dev | Electrodes for making electrical contact to the living body of a mammal |
US3568735A (en) * | 1968-06-26 | 1971-03-09 | Cooke Eng Co | Laboratory microtitration dispensing apparatus |
US3568732A (en) | 1969-02-28 | 1971-03-09 | Kelly James A Jun | Splice straightener for aerial conductors |
US3659600A (en) | 1970-02-24 | 1972-05-02 | Estin Hans H | Magnetically operated capsule for administering drugs |
US3727614A (en) | 1971-05-13 | 1973-04-17 | Merck & Co Inc | Multiple dosage inoculator |
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US3738493A (en) | 1971-09-24 | 1973-06-12 | Analytical Instr Spec | Apparatus for simultaneous application of samples to thin layer chromatography plates |
BE795384A (en) | 1972-02-14 | 1973-08-13 | Ici Ltd | DRESSINGS |
CH557178A (en) | 1972-08-10 | 1974-12-31 | Siemens Ag | DEVICE FOR DISPENSING DRUGS. |
US3923060A (en) | 1974-04-23 | 1975-12-02 | Jr Everett H Ellinwood | Apparatus and method for implanted self-powered medication dispensing having timing and evaluator means |
US4140109A (en) | 1977-10-17 | 1979-02-20 | Savic Michael I | Impedance-based method and apparatus for monitoring cryodestruction in controlled cryosurgery |
FR2460343A1 (en) | 1979-06-29 | 1981-01-23 | Solvay | CATHODE FOR THE ELECTROLYTIC PRODUCTION OF HYDROGEN |
JPS5683360A (en) * | 1979-12-10 | 1981-07-07 | Olympus Optical Co | Pneumoperitoneum needle |
US4447225A (en) | 1982-03-22 | 1984-05-08 | Taff Barry E | Multidose jet injector |
US4619652A (en) | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
US4505710A (en) | 1983-05-13 | 1985-03-19 | Collins Earl R | Implantable fluid dispensing system |
DE3502913C1 (en) | 1985-01-29 | 1986-07-03 | Günter Prof. Dr.rer.nat. 5100 Aachen Rau | Sensor for non-invasive detection of electrophysiological values |
US4777599A (en) | 1985-02-26 | 1988-10-11 | Gillette Company | Viscoelastometry of skin using shear wave propagation |
FR2594341B1 (en) * | 1986-02-14 | 1990-08-10 | Charton Jean Pierre | INJECTOR APPARATUS FOR THE PRACTICE OF MESOTHERAPY |
AT384737B (en) | 1986-04-04 | 1987-12-28 | Thoma Dipl Ing Dr Techn Herwig | DEVICE FOR CONTINUOUSLY DELIVERING LIQUID MEDICINAL PRODUCTS |
DE3789477T2 (en) * | 1986-09-18 | 1994-07-14 | Paul G Yock | Device for use in drains of blood vessels. |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US4808156A (en) | 1987-03-09 | 1989-02-28 | Dean Consuelo M | Cannular instrument and method for inserting a cannular instrument into a vein |
US6056716A (en) | 1987-06-08 | 2000-05-02 | D'antonio Consultants International Inc. | Hypodermic fluid dispenser |
DD262803A1 (en) | 1987-08-05 | 1988-12-14 | Transform Roentgen Matern Veb | INJECTION DEVICE |
US5312486A (en) | 1987-12-24 | 1994-05-17 | Frank Meyer | Water-containing, hardenable foam compositions with inorganic components and process for their preparation |
US4989614A (en) | 1988-02-23 | 1991-02-05 | Vance Products Incorporated | Fine-needle aspiration cell sampling methods |
CA2008262A1 (en) * | 1989-01-30 | 1990-07-30 | John A. Gilly | Clinical applicator |
US5425706A (en) | 1989-02-24 | 1995-06-20 | S. I. Scientific Innovations Ltd. | Dispensing device particularly useful for dispensing nutritional liquids |
US5062834A (en) | 1989-02-24 | 1991-11-05 | Product Development (S.G.Z.) Ltd | Device for dispensing a liquid particularly useful for delivering medicaments at a predetermined rate |
JPH0648975B2 (en) | 1989-10-02 | 1994-06-29 | 俊郎 樋口 | Micro injection device and injection control method thereof |
US5262128A (en) | 1989-10-23 | 1993-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Array-type multiple cell injector |
EP0429842B1 (en) | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
US6090790A (en) | 1989-12-14 | 2000-07-18 | Eriksson; Elof | Gene delivery by microneedle injection |
US5092901A (en) | 1990-06-06 | 1992-03-03 | The Royal Institution For The Advancement Of Learning (Mcgill University) | Shape memory alloy fibers having rapid twitch response |
TW279133B (en) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
US5156591A (en) | 1990-12-13 | 1992-10-20 | S. I. Scientific Innovations Ltd. | Skin electrode construction and transdermal drug delivery device utilizing same |
US5279544A (en) | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5279547A (en) | 1991-01-03 | 1994-01-18 | Alcon Surgical Inc. | Computer controlled smart phacoemulsification method and apparatus |
SE9101022D0 (en) * | 1991-01-09 | 1991-04-08 | Paal Svedman | MEDICAL SUSPENSION DEVICE |
US5312456A (en) | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
US5533995A (en) | 1991-11-13 | 1996-07-09 | Elan Corporation, Plc | Passive transdermal device with controlled drug delivery |
US6048337A (en) | 1992-01-07 | 2000-04-11 | Principal Ab | Transdermal perfusion of fluids |
KR0145453B1 (en) | 1992-01-21 | 1998-07-01 | 알렌 제이 | Electrosurgical trocar control device |
US5252023A (en) * | 1992-02-10 | 1993-10-12 | Kelly Kevin M | Lifting apparatus |
JP2572823Y2 (en) | 1992-02-13 | 1998-05-25 | 株式会社アドバンス | Simple blood sampler |
WO1993020784A1 (en) | 1992-04-10 | 1993-10-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
US5478328A (en) | 1992-05-22 | 1995-12-26 | Silverman; David G. | Methods of minimizing disease transmission by used hypodermic needles, and hypodermic needles adapted for carrying out the method |
JPH0698920A (en) * | 1992-09-21 | 1994-04-12 | Hayashi Shigetada | Acupuncture precise measuring instrument |
US5354273A (en) | 1992-12-14 | 1994-10-11 | Mallinckrodt Medical, Inc. | Delivery apparatus with pressure controlled delivery |
US5478323A (en) * | 1993-04-02 | 1995-12-26 | Eli Lilly And Company | Manifold for injection apparatus |
IE68890B1 (en) | 1993-04-08 | 1996-07-24 | Elan Med Tech | Intradermal delivery device |
US5335668A (en) * | 1993-04-30 | 1994-08-09 | Medical Scientific, Inc. | Diagnostic impedance measuring system for an insufflation needle |
JP3494183B2 (en) * | 1993-08-10 | 2004-02-03 | 株式会社アドバンス | Simple blood collection device |
CA2171563A1 (en) | 1993-09-14 | 1995-03-23 | Eric Le Cheminant | Injection device |
US5389222A (en) | 1993-09-21 | 1995-02-14 | The United States Of America As Represented By The United States Department Of Energy | Spring-loaded polymeric gel actuators |
US5599346A (en) | 1993-11-08 | 1997-02-04 | Zomed International, Inc. | RF treatment system |
US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
US5611806A (en) | 1994-05-23 | 1997-03-18 | Samsung Electro-Mechanics Co., Ltd. | Skin perforating device for transdermal medication |
CA2149836C (en) | 1994-05-23 | 1999-07-06 | Sang Bae Choi | Perforating device for dermal administration |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
US5649423A (en) | 1994-06-07 | 1997-07-22 | Sandia Corporation | Micromechanism linear actuator with capillary force sealing |
DE4420232A1 (en) | 1994-06-07 | 1995-12-14 | Robert Waltereit | Penetration depth checking device for hollow needle or probe inserted in human or animal patient |
US5478315A (en) | 1994-08-08 | 1995-12-26 | Brothers Family Investments, L.C. | Local anesthetic injection system |
US5432098A (en) | 1994-10-31 | 1995-07-11 | Dynatech Precision Sampling Corporation | Apparatus, and process, for automatically sampling solids and semi-solids materials for analysis |
IE72524B1 (en) * | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
GB9508606D0 (en) | 1995-04-27 | 1995-06-14 | Svedman Paul | Suction blister sampling |
WO1996037256A1 (en) | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical patch for enhancing the delivery of compounds through the skin |
AU5740496A (en) | 1995-05-22 | 1996-12-11 | General Hospital Corporation, The | Micromechanical device and method for enhancing delivery of compounds through the skin |
US5827216A (en) * | 1995-06-07 | 1998-10-27 | Cormedics Corp. | Method and apparatus for accessing the pericardial space |
US5858001A (en) * | 1995-12-11 | 1999-01-12 | Elan Medical Technologies Limited | Cartridge-based drug delivery device |
JPH09192218A (en) * | 1996-01-16 | 1997-07-29 | Hitachi Ltd | Blood-sugar level control system |
JPH09239031A (en) * | 1996-03-09 | 1997-09-16 | Honda Electron Co Ltd | Injector mounting ultrasonic vibrator transducer |
US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
US6117155A (en) | 1996-05-01 | 2000-09-12 | Lee; Young H. | Coated needle for use with an intramuscular stimulation treatment device |
US5785688A (en) | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US5954668A (en) | 1996-06-14 | 1999-09-21 | Medrad, Inc. | Extravasation detector using microwave radiometry |
ATE234129T1 (en) | 1996-06-18 | 2003-03-15 | Alza Corp | DEVICE FOR IMPROVING TRANSDERMAL ADMINISTRATION OF MEDICATIONS OR EXTRACTION OF BODY FLUID |
US6183434B1 (en) | 1996-07-03 | 2001-02-06 | Spectrx, Inc. | Multiple mechanical microporation of skin or mucosa |
JPH1043296A (en) * | 1996-08-05 | 1998-02-17 | Terumo Corp | Chemical injecting apparatus |
ATE231015T1 (en) | 1996-09-17 | 2003-02-15 | Deka Products Lp | SYSTEM FOR DELIVERY OF MEDICATION THROUGH TRANSPORT |
US6071251A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
SE9604564D0 (en) | 1996-12-12 | 1996-12-12 | Paal Svedman | Method and apparatus for conducting electrical currents |
US6246904B1 (en) | 1996-12-17 | 2001-06-12 | Alza Corporation | Electrotransport drug delivery reservoirs containing inert fillers |
US5928194A (en) | 1997-04-07 | 1999-07-27 | Maget; Henri J. R. | Self-contained liquid microdispenser |
US5928207A (en) | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
US5972013A (en) | 1997-09-19 | 1999-10-26 | Comedicus Incorporated | Direct pericardial access device with deflecting mechanism and method |
JPH11137684A (en) * | 1997-11-12 | 1999-05-25 | Hiroshi Oya | Indolent and safe syringe |
EP1032441B1 (en) * | 1997-11-26 | 2004-03-03 | E-Z-Em, Inc. | Extravasation detection device |
US6918901B1 (en) * | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
ATE221400T1 (en) | 1997-12-11 | 2002-08-15 | Alza Corp | DEVICE FOR INCREASE THE TRANSDERMAL FLOW OF ACTIVE INGREDIENTS |
DK1037686T3 (en) | 1997-12-11 | 2006-01-02 | Alza Corp | Apparatus for enhancing transdermal flow of agents |
US6126629A (en) | 1997-12-18 | 2000-10-03 | Bausch & Lomb Surgical, Inc. | Multiple port phaco needle |
US6154673A (en) * | 1997-12-30 | 2000-11-28 | Agilent Technologies, Inc. | Multilingual defibrillator |
US6048204A (en) * | 1998-02-03 | 2000-04-11 | Lifecore Biomedical, Inc. | Self tapping screw type dental implant |
US5957895A (en) | 1998-02-20 | 1999-09-28 | Becton Dickinson And Company | Low-profile automatic injection device with self-emptying reservoir |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US5971998A (en) | 1998-03-31 | 1999-10-26 | Donald G. Russell | Support device and method for controlling breast thickness during stereotactic guided needle biopsy |
WO1999058050A1 (en) | 1998-05-13 | 1999-11-18 | Cygnus, Inc. | Signal processing for measurement of physiological analytes |
DK1077634T3 (en) | 1998-05-13 | 2003-11-24 | Cygnus Therapeutic Systems | Monitoring of physiological analytes |
EP1082151A1 (en) | 1998-06-04 | 2001-03-14 | ELAN CORPORATION, Plc | Gas driven drug delivery device |
AU767122B2 (en) | 1998-06-10 | 2003-10-30 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
GB9815819D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
GB9815820D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Improvements relating to micro-machining |
WO2000006227A1 (en) | 1998-07-27 | 2000-02-10 | Medi-Ject Corporation | Loading mechanism for medical injector assembly |
JP2002526273A (en) | 1998-09-18 | 2002-08-20 | ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション | Microneedle with surface micromachining |
DE19843733A1 (en) * | 1998-09-24 | 2000-03-30 | Voith Sulzer Papiertech Patent | Wiper blade assembly coating paper or card bands with optionally-viscous liquid, employs system of leaf spring tensioning which forms ductor chamber and is readily replaced and adjusted |
US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
US6317630B1 (en) | 1999-01-29 | 2001-11-13 | Yossi Gross | Drug delivery device |
US6132449A (en) | 1999-03-08 | 2000-10-17 | Agilent Technologies, Inc. | Extraction and transportation of blood for analysis |
US6319230B1 (en) | 1999-05-07 | 2001-11-20 | Scimed Life Systems, Inc. | Lateral needle injection apparatus and method |
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
DE60044084D1 (en) | 1999-06-04 | 2010-05-12 | Georgia Tech Res Inst | DEVICES FOR THE ENLARGED PENETRATION OF MICRONEDES IN BIOLOGICAL HARDENING |
US6379324B1 (en) | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6607495B1 (en) * | 1999-06-18 | 2003-08-19 | University Of Virginia Patent Foundation | Apparatus for fluid transport and related method thereof |
US6408204B1 (en) | 1999-07-28 | 2002-06-18 | Medrad, Inc. | Apparatuses and methods for extravasation detection |
DE60022540T2 (en) * | 1999-11-15 | 2006-06-14 | Velcro Ind | FASTENING ELEMENT FOR THE SKIN |
EP1239775B1 (en) * | 1999-12-16 | 2005-03-16 | ALZA Corporation | Device for enhancing transdermal flux of sampled agents |
US7003336B2 (en) * | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US6572740B2 (en) | 2000-04-13 | 2003-06-03 | Elan Pharma International Limited | Electrolytic cell |
US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6440096B1 (en) * | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
JP2002028247A (en) * | 2000-07-18 | 2002-01-29 | Japan Science & Technology Corp | Method and instrument for sensing venous pricking by puncture needle |
EP2578252B1 (en) | 2000-11-30 | 2019-01-09 | Valeritas, Inc. | Device with substantially freely movable micro-probe over the housing |
EP1395320B1 (en) | 2001-06-11 | 2006-06-28 | Glaxo Group Limited | Medicament dispenser |
US6835193B2 (en) | 2001-07-10 | 2004-12-28 | Myocardial Therapeutics, Inc. | Methods for controlled depth injections into interior body cavities |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US7364586B2 (en) * | 2001-12-21 | 2008-04-29 | The Trustees Of Columbia University In The City Of New York | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis |
EP1403519A1 (en) * | 2002-09-27 | 2004-03-31 | Novo Nordisk A/S | Membrane pump with stretchable pump membrane |
-
2002
- 2002-09-09 US US10/238,844 patent/US7429258B2/en not_active Expired - Fee Related
- 2002-10-18 AT AT02789233T patent/ATE420680T1/en not_active IP Right Cessation
- 2002-10-18 WO PCT/US2002/033544 patent/WO2003037403A1/en active Application Filing
- 2002-10-18 EP EP02789233A patent/EP1439871B1/en not_active Expired - Lifetime
- 2002-10-18 DE DE60230896T patent/DE60230896D1/en not_active Expired - Lifetime
- 2002-10-18 AU AU2002353840A patent/AU2002353840B2/en not_active Ceased
- 2002-10-18 JP JP2003539742A patent/JP2005525141A/en active Pending
- 2002-10-18 CA CA2464483A patent/CA2464483C/en not_active Expired - Fee Related
- 2002-10-21 DE DE60225172T patent/DE60225172D1/en not_active Expired - Lifetime
- 2002-10-21 CA CA2464485A patent/CA2464485C/en not_active Expired - Fee Related
- 2002-10-21 WO PCT/US2002/033794 patent/WO2003037404A1/en active IP Right Grant
- 2002-10-21 JP JP2003539743A patent/JP4612304B2/en not_active Expired - Fee Related
- 2002-10-21 US US10/278,050 patent/US7066922B2/en not_active Expired - Lifetime
- 2002-10-21 US US10/278,049 patent/US7364568B2/en not_active Expired - Fee Related
- 2002-10-21 US US10/277,724 patent/US20030083618A1/en not_active Abandoned
- 2002-10-21 EP EP02782208A patent/EP1446176B1/en not_active Expired - Lifetime
- 2002-10-21 AT AT02782208T patent/ATE386561T1/en not_active IP Right Cessation
- 2002-10-21 US US10/277,722 patent/US7645263B2/en not_active Expired - Fee Related
- 2002-10-22 DE DE60230795T patent/DE60230795D1/en not_active Expired - Lifetime
- 2002-10-22 EP EP02784221A patent/EP1448253B1/en not_active Expired - Lifetime
- 2002-10-22 CA CA2464670A patent/CA2464670C/en not_active Expired - Fee Related
- 2002-10-22 JP JP2003539745A patent/JP2005507715A/en active Pending
- 2002-10-22 AT AT02784221T patent/ATE419885T1/en not_active IP Right Cessation
- 2002-10-22 AU AU2002353855A patent/AU2002353855B2/en not_active Ceased
- 2002-10-22 EP EP02789250A patent/EP1443990A1/en not_active Ceased
- 2002-10-22 AU AU2002348009A patent/AU2002348009B9/en not_active Ceased
- 2002-10-22 WO PCT/US2002/033823 patent/WO2003037405A1/en active Application Filing
- 2002-10-22 CA CA002464487A patent/CA2464487A1/en not_active Abandoned
- 2002-10-22 JP JP2003539746A patent/JP4610193B2/en not_active Expired - Fee Related
- 2002-10-22 WO PCT/US2002/033829 patent/WO2003037406A2/en not_active Application Discontinuation
- 2002-10-22 CA CA2464673A patent/CA2464673C/en not_active Expired - Fee Related
- 2002-10-22 WO PCT/US2002/033830 patent/WO2003037407A1/en active Application Filing
- 2002-10-22 JP JP2003539744A patent/JP4610192B2/en not_active Expired - Fee Related
- 2002-10-22 EP EP02784220A patent/EP1438092A2/en not_active Withdrawn
-
2005
- 2005-10-19 JP JP2005304325A patent/JP2006081918A/en active Pending
-
2008
- 2008-01-11 US US11/972,726 patent/US7651475B2/en not_active Expired - Fee Related
- 2008-04-29 US US12/150,606 patent/US8246582B2/en not_active Expired - Fee Related
-
2009
- 2009-05-11 JP JP2009114991A patent/JP2009219887A/en active Pending
- 2009-05-11 JP JP2009114992A patent/JP2009219888A/en active Pending
- 2009-05-11 JP JP2009114989A patent/JP2009219886A/en active Pending
- 2009-05-11 JP JP2009114990A patent/JP2009240790A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2464485C (en) | Microneedle transdermal transport device | |
AU2002353855A1 (en) | Impedance sensor | |
AU2002348009A1 (en) | Transdermal transport device with suction | |
AU2002353840A1 (en) | Microneedle transport device | |
AU2002348386A1 (en) | Microneedle transdermal transport device | |
AU2002348008A1 (en) | Transdermal transport device with an electrolytic actuator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |